



www.sughrue.com

December 10, 2001

BOX PCT

Commissioner for Patents
Washington, D.C. 20231

PCT/JP00/07917
-filed November 10, 2000

Re: Application of Noboru YAMAJI, Kouichi NISHIMURA, Kunitake ABE, Osamu OHARA, Takahiro NAGASE and Nobuo NOMURA
NOVEL METALLOPROTEASE HAVING AGGREGANASE ACTIVITY
Assignee: 1) YAMANOUCHI PHARMACEUTICAL CO., LTD.
2) KAZUSA DNA RESEARCH INSTITUTE
Our Ref: O67541

Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. § 371 and in accordance with Chapter II of the Patent Cooperation Treaty:

- ☒ an executed Declaration and Power of Attorney.
- ☒ an English translation of the International Application.
- ☒ eight (8) sheets of drawings.
- ☒ a Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821-1.825 with attached twenty-eight (28) pages of Sequence Listing and a 3.5" disk containing the Sequence Listing.
- ☒ an English translation of Article 19 claim amendments(4 pages).
- ☒ Notification Concerning Submission or Transmittal of Priority Document.
- ☒ an executed Assignment and PTO 1595 form.
- ☒ International Search Report, Information Disclosure Statement and a Form PTO-1449.

It is assumed that copies of the International Application, the International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by § 371(c) will be supplied directly by the International Bureau, but if further copies are needed, the undersigned can easily provide them upon request.

The Government filing fee is calculated as follows:

[illegible]

10/009332



Q67541

Page 2

Checks for the statutory filing fee of \$1308.00 and Assignment recordation fee of \$40.00 are attached. You are also directed and authorized to charge or credit any difference or overpayment to Deposit Account No. 19-4880. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.492 which may be required during the entire pendency of the application to Deposit Account No. 19-4880. A duplicate copy of this transmittal letter is attached.

Priority is claimed from:

<u>Country</u>	<u>Application No</u>	<u>Filing Date</u>
Japan	P. Hei. 11-321740	November 11, 1999
Japan	P. 2000-144020	May 16, 2000

Respectfully submitted,

A handwritten signature in cursive script, reading 'Mark Boland'.

Mark Boland
Registration No. 32,197

MXB/amt

1009332-1001

8/PRTS

JCO7 Rec'd PCT/PTO 10 DEC 2001

10/009332

Description

Novel Metalloprotease Having Aggrecanase Activity

5 Technical Field

10 This invention relates to a novel metalloprotease having an aggrecanase activity and causing joint diseases (to be referred to as "joint disease aggrecanase" hereinafter), a gene coding for this "joint disease aggrecanase", a method for producing the "joint disease aggrecanase", a method for screening a substance capable of inhibiting the aggrecanase activity with the use of the "joint disease aggrecanase", a pharmaceutical composition for inhibiting degradation of proteoglycans, which
15 comprises the substance capable of inhibiting the aggrecanase activity as the active ingredient, and a promoter gene of the "joint disease aggrecanase".

Background Art

20 Joint diseases are diseases which show damage and degeneration of joint cartilage as the main morbid states. Though a disease having the most frequent number of patients among joint diseases is osteoarthritis (OA), analgesic anti-inflammatory drugs and hyaluronic acid
25 preparations are used in the current therapeutic method merely as a symptomatic therapy for the purpose of

alleviating pains accompanied by the degeneration of cartilage and the destruction of bone under cartilage, so that it cannot be said that they are exerting sufficient therapeutic effects.

5 Joint cartilage is a tissue mainly composed of type II collagen and aggrecan which is a cartilage-specific proteoglycan, and degradation and degeneration of both of them are observed in the joint diseases. Because of this, it has been considered for a long time that control of the
10 degradation and degeneration of these extracellular matrix components would lead to the treatment of joint diseases, so that attempts have been positively made to identify degradation-concerned proteases (collagenase and
15 aggrecanase) and to screen their inhibitors and develop them as medicaments.

As proteases having collagenase activities, matrix metalloproteases (MMP1, MMP8, MMP13, MMP14 and the like) have been identified, and their selective inhibitors have been discovered. However, in spite of the attempts to
20 develop a large number of MMP inhibitors having collagenase inhibition activities as therapeutic drugs for joint diseases including OA and rheumatic arthritis (RA), MMP inhibitors to be used in these diseases as the indication have not been put on the market. Under such circumstances,
25 attention has been directed toward aggrecanase which

selectively degrades aggrecan which is another main
constituting component of joint cartilage.

A joint disease-related role of an enzyme aggrecanase
which cleaves aggrecan at the site between Glu³⁷³-Ala³⁷⁴ has
5 been revealed by the reports of Sandy et al. and Lohmander
et al. stating that all of the main digested aggrecan
fragments found in the synovial fluid of human arthritis
patients were generated by cleaving at the aggrecanase
digestion site (Sandy J.D. et al., *J. Clin. Invest.*, 89,
10 1512 - 1516, 1992; Lohmander L.S. et al., *Arthritis*
Rheum., 36, 1214 - 1222, 1993). On the other hand, it has
been known that, in an *in vitro* explant culture system of
joint cartilage, degradation of aggrecan firstly occurs by
IL-1 induction and then degradation of type II collagen is
15 accelerated (Dingle L.T. et al., *Ann. Rheum. Dis.*, 34, 303
- 311, 1975; Cawston T.E. et al., *Biochem. Biophys. Res.*
Comm., 215, 377 - 385, 1995; Kozaci L.D. et al., *Arthritis*
Rheum., 40, 164 - 174, 1997). It has been reported that
the aggrecan degradation takes the precedence of the type
20 II collagen degradation in a mouse arthritis model too (van
Meurs J.B. et al., *Arthritis Rheum.*, 42, 1128 - 1139,
1999). These reports suggest a possibility that the type
II collagen degradation can be controlled by inhibiting the
preceding aggrecan degradation.

25 However, the entity of the aggrecanase which causes
joint diseases ("joint disease aggrecanase") has been

unclear for long time, though its biochemical properties
had been elucidated, namely it is a metalloprotease, it
exists in outside of cells, a glycosaminoglycan side chain
is concerned in its substrate recognition, its activity is
5 induced by IL-1, TNF and retinoic acid, and the like.

Recently, ADAMTS4 (aggrecanase-1: Tortorella M.D. et al.,
Science, 284, 1664 - 1666, 1999) and ADAMTS11 (aggrecanase-
2: Abbaszade I. et al., *J. Biol. Chem.*, 274, 23443 - 23450,
1999) have been reported as proteases having an aggrecanase
10 activity. However, it was revealed that they are not the
"joint disease aggrecanase", because their gene expression
in human OA cartilage is not increased, and their gene
expression in an *in vitro* explant culture system of human
knee joint cartilage is not induced by IL-1, TNF and
15 retinoic acid which induce the aggrecanase activity that
causes joint diseases (Flannery C.R. et al., *Biochem.*
Biophys. Res. Commun., 260, 318 - 322, 1999). As described
above, the "joint disease aggrecanase" has not been
obtained.

Disclosure of the Invention

Under such circumstances, the present inventors have
conducted intensive studies and, as a result, succeeded in
isolating a gene coding for a novel metalloprotease having
25 the aggrecanase activity, which is the "joint disease

aggrecanase", determining its full-length ORF sequence and thereby achieved production of a recombinant protein.

Also, a vector comprising this gene, a host cell comprising this vector and a method for producing the novel protein using this host cell were established.

Also, the inventors have succeeded in providing a screening method which uses this protein and found that a compound selected by carrying out this screening method significantly inhibits the "aggrecanase activity" (namely, the activity of this protein to cleave the extracellular substrate aggrecan selectively at the site between Glu³⁷³-Ala³⁷⁴) and can become a medicament useful in preventing and/or treating joint diseases.

In addition, a promoter gene of the protein, which is useful in screening a medicament for preventing and/or treating joint diseases was isolated, resulting in accomplishment of the present invention.

Accordingly, the invention relates to:

[1] a metalloprotease having an aggrecanase activity, which comprises an amino acid sequence of from the 213th position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, or an equivalent of the metalloprotease,

[2] a metalloprotease having an aggrecanase activity, which comprises an amino acid sequence of from the 1st position to the 583rd position of the amino acid sequence

represented by SEQ ID NO:1, or an equivalent of the metalloprotease,

[3] a metalloprotease having an aggrecanase activity, which consists of the amino acid sequence represented by SEQ ID

5 NO:1, an amino acid sequence of from the 1st position to the 687th position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 1st position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 213th position to the 950th position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 213th position to the 687th position of the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence of from the 213th position to the 583rd position of the amino acid sequence represented by SEQ ID
10 NO:1, or an equivalent of the metalloprotease,

[4] a gene which encodes the metalloprotease having an aggrecanase activity described in any one of [1] to [3] or an amino acid sequence of an equivalent of the

20 metalloprotease,

[5] a vector which comprises the gene described in [4],

[6] a host cell which comprises the vector described in [5],

[7] a method for producing the metalloprotease having an
25 aggrecanase activity described in any one of [1] to [3] or

an equivalent of the metalloprotease, which comprises using the host cell described in [6],

[8] an antibody against the metalloprotease having an aggrecanase activity described in any one of [1] to [3] or

5 an equivalent of the metalloprotease,

[9] a method for screening a substance capable of inhibiting an aggrecanase activity of the metalloprotease, which comprises allowing the metalloprotease having an aggrecanase activity described in any one of [1] to [3] or

10 an equivalent of the metalloprotease to contact with a compound to be tested,

[10] a pharmaceutical composition for inhibiting degradation of proteoglycans, which comprises a substance capable of inhibiting the metalloprotease having an

15 aggrecanase activity described in any one of [1] to [3] or an equivalent of the metalloprotease, as an active ingredient, and

[11] a gene represented by SEQ ID NO:24, 25, 26, 27, 28, 29, 30 or 31, or an equivalent of the gene.

20 The invention also relates to the use of a substance capable of inhibiting an aggrecanase activity of the metalloprotease having an aggrecanase activity described in any one of [1] to [3] or of an equivalent of the metalloprotease, in producing a medicament for inhibiting
25 degradation of proteoglycans.

The invention also relates to the use of a substance capable of inhibiting the metalloprotease having an aggrecanase activity or an equivalent of the metalloprotease, which is obtainable by the screening method described in [9], in treating joint diseases.

The invention also relates to a method for screening a substance capable of modifying a promoter activity of the gene described in [11], which uses this gene.

10 Mode for Carrying Out the Invention

The following describes the terms used in the invention. The term "aggrecanase" as used herein means a metalloprotease which has a zinc binding consensus sequence (HExxH) and also has an activity to cleave aggrecan existing in joint cartilage selectively at the site between Glu³⁷³-Ala³⁷⁴, namely the "aggrecanase activity". Also, unless otherwise noted, the "aggrecanase" is referred to as "protein".

The "joint disease aggrecanase" of the invention is any of a metalloprotease having an aggrecanase activity, which comprises an amino acid sequence of from the 213th position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, or an equivalent of the metalloprotease.

Also, the "joint disease aggrecanase" of the invention is preferably a metalloprotease having an

aggrecanase activity, which comprises an amino acid sequence of from the 1st position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, or an equivalent of the metalloprotease.

5 More preferably, it is a metalloprotease having an aggrecanase activity, which consists of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 1st position to the 687th position of the amino acid sequence represented by SEQ ID NO:1, an amino acid
10 sequence of from the 1st position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 213th position to the 950th position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 213th position to
15 the 687th position of the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence of from the 213th position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, or an equivalent of the metalloprotease.

20 Regarding the "equivalent of the metalloprotease",
 (1) in the case of an equivalent of the metalloprotease comprising an amino acid sequence of from the 213th position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, it is a metalloprotease in
25 which one to several amino acid residues (preferably from 1 to 10, more preferably from 1 to 5) are substituted,

deleted and/or inserted at one to several positions
(preferably from 1 to 10, more preferably from 1 to 5) in
the amino acid sequence of from the 213th position to the
583rd position, and which has the aggrecanase activity, (2)
5 in the case of an equivalent of the metalloprotease
comprising an amino acid sequence of from the 1st position
to the 583rd position of the amino acid sequence
represented by SEQ ID NO:1, it is a metalloprotease in
which one to several amino acid residues (preferably from 1
10 to 10, more preferably from 1 to 5) are substituted,
deleted and/or inserted at one to several positions
(preferably from 1 to 10, more preferably from 1 to 5) in
the amino acid sequence of from the 1st position to the
583rd position, and which has the aggrecanase activity, or
15 (3) in the case of an equivalent of the metalloprotease
consisting of the amino acid sequence represented by SEQ ID
NO:1, an amino acid sequence of from the 1st position to
the 687th position of the amino acid sequence represented
by SEQ ID NO:1, an amino acid sequence of from the 1st
20 position to the 583rd position of the amino acid sequence
represented by SEQ ID NO:1, an amino acid sequence of from
the 213th position to the 950th position of the amino acid
sequence represented by SEQ ID NO:1, an amino acid sequence
of from the 213th position to the 687th position of the
25 amino acid sequence represented by SEQ ID NO:1 or an amino
acid sequence of from the 213th position to the 583rd

position of the amino acid sequence represented by SEQ ID NO:1, it is a metalloprotease in which one to several amino acid residues (preferably from 1 to 10, more preferably from 1 to 5) are substituted, deleted and/or inserted at one to several positions (preferably from 1 to 10, more preferably from 1 to 5) in respective sequences, and which has the aggrecanase activity.

Origin of the "joint disease aggrecanase" of the invention is not limited to human. For example, it includes a metalloprotease having the aggrecanase activity which is originated from an organism other than human (e.g., mouse, rat, hamster and dog) and cause joint diseases. Also included is a protein artificially modified by a genetic engineering means based on the sequence of "joint disease aggrecanase" described in SEQ ID NO:1.

Also, the gene coding for the "joint disease aggrecanase" of the invention is any gene which encodes the "joint disease aggrecanase", namely a gene which encodes a metalloprotease having an aggrecanase activity, which comprises an amino acid sequence of from the 213th position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, or an equivalent of the metalloprotease.

Also, the gene coding for the "joint disease aggrecanase" of the invention may be any gene coding for a metalloprotease having an aggrecanase activity, which

comprises an amino acid sequence of from the 1st position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, or an equivalent of the metalloprotease.

5 In addition, it may be any gene coding for a metalloprotease having an aggrecanase activity, which consists of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 1st position to the 687th position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 1st position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 213th position to the 950th position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 213th position to the 687th position of the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence of from the 213th position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, or an equivalent of the metalloprotease.

20 Regarding the "gene coding for an equivalent of the metalloprotease", (1) in the case of a gene coding for an equivalent of the metalloprotease comprising an amino acid sequence of from the 213th position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, it is a gene coding for a metalloprotease in which one to several amino acid residues (preferably from 1 to 10, more

preferably from 1 to 5) are substituted, deleted and/or inserted at one to several positions (preferably from 1 to 10, more preferably from 1 to 5) in the amino acid sequence of from the 213th position to the 583rd position, and which has the aggrecanase activity, (2) in the case of a gene coding for an equivalent of the metalloprotease comprising an amino acid sequence of from the 1st position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, it is a gene coding for a metalloprotease in which one to several amino acid residues (preferably from 1 to 10, more preferably from 1 to 5) are substituted, deleted and/or inserted at one to several positions (preferably from 1 to 10, more preferably from 1 to 5) in the amino acid sequence of from the 1st position to the 583rd position, and which has the aggrecanase activity, or (3) in the case of a gene coding for an equivalent of the metalloprotease consisting of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 1st position to the 687th position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 1st position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 213th position to the 950th position of the amino acid sequence represented by SEQ ID NO:1, an amino acid sequence of from the 213th position to the 687th position of the amino acid sequence represented by SEQ ID

NO:1 or an amino acid sequence of from the 213th position to the 583rd position of the amino acid sequence represented by SEQ ID NO:1, it is a gene coding for a metalloprotease in which one to several amino acid residues (preferably from 1 to 10, more preferably from 1 to 5) are substituted, deleted and/or inserted at one to several positions (preferably from 1 to 10, more preferably from 1 to 5) in respective sequences, and which has the aggrecanase activity.

The gene coding for the "joint disease aggrecanase" of the invention is preferably a gene consisting from the 1st position to the 1749th position, from the 1st position to the 2061st position, from the 1st position to the 2850th position, from the 637th position to the 1749th position, from the 637th position to the 2061st position or from the 637th position to the 2850th position, of the nucleotide sequence described in SEQ ID NO:2, more preferably a gene consisting from the 637th position to the 1749th position, from the 637th position to the 2061st position or from the 637th position to the 2850th position, of the nucleotide sequence described in SEQ ID NO:2.

The promoter gene of the invention is preferably a gene having a nucleotide sequence described in SEQ ID NO:24, 25, 26, 27, 28, 29, 30 or 31. The "equivalent of the gene described in SEQ ID NO:24, 25, 26, 27, 28, 29, 30 or 31" is a gene in which one to several bases (preferably

from 1 to 10, more preferably from 1 to 5) are substituted, deleted and/or inserted at one to several positions (preferably from 1 to 10, more preferably from 1 to 5) in the nucleotide sequence described in SEQ ID NO:24, 25, 26, 27, 28, 29, 30 or 31, and which has a "joint disease aggrecanase" promoter activity. The term "promoter activity" means an activity which acts as the initiation region for transcribing information of DNA chains to RNA chains.

According to a result of BLAST (basic local alignment search tool) (S.F. Altschul et al., (1990), *J. Mol. Biol.*, 215, 403 - 410) retrieving of GENBANK and SwissProt, the amino acid sequence (SEQ ID NO:1) (950 amino acids) of MDT56 as one of the "joint disease aggrecanase" of the invention and the nucleotide sequence (SEQ ID NO:2) (2853 base pairs) which encodes this amino acid sequence are novel. When homology of the amino acid sequence with the ADAMTS4 and ADAMTS11 described in the foregoing was examined, its sequence similarity was 50% or less.

A metalloprotease having an aggrecanase activity, which has high homology with the metalloprotease having the amino acid sequence represented by SEQ ID NO:1, is also included in the "joint disease aggrecanase" of the invention. The high homology metalloprotease having an aggrecanase activity is a metalloprotease having an aggrecanase activity which shows at least 70% or more,

preferably 80% or more, more preferably 90% or more, most preferably 95% or more, particularly preferably 99% or more, of sequence homology with the amino acid sequence represented by SEQ ID NO:1. The homology can be specified using the aforementioned BLAST retrieving algorithm.

In addition, the "joint disease aggrecanase" of the invention can be used for the screening of a substance which inhibits the aggrecanase activity that causes joint diseases. The substance which inhibits the aggrecanase activity is useful as a composition for inhibiting degradation of proteoglycans.

In addition, the promoter gene of the "joint disease aggrecanase" of the invention is worthy of notice in that it can be used for the screening of a substance which inhibits the promoter activity. The term "a substance which inhibits the promoter activity" as used herein means a substance which inhibits expression of the "joint disease aggrecanase" by inhibiting action of the promoter. A method for screening a substance capable of inhibiting promoter activity, which uses the promoter gene of the aggrecanase, and use of the substance capable of inhibiting the promoter activity for preventing and/or treating joint diseases are also included in the invention. Furthermore, the "joint disease aggrecanase" promoter gene exists in two or more mutant forms, namely genetic polymorphism. Thus, it can be used for the analysis of correlation between the

genetic polymorphism and diseases in which concern of the aggrecanase is considered so that, including joint diseases, as a result, there is a possibility that it can be used as a marker for gene diagnosis.

5 Regarding the gene coding for the "joint disease aggrecanase" of the invention, the vector of the invention, the host cell of the invention, the method of the invention for producing the "joint disease aggrecanase", the method of the invention for detecting the aggrecanase activity of
10 the "joint disease aggrecanase", the method of the invention for producing an antibody which reacts with the "joint disease aggrecanase", the method of the invention for screening a substance which inhibits the aggrecanase activity of the "joint disease aggrecanase", the method of
15 the invention for detecting the promoter activity and the method of the invention for screening a substance which modifies the promoter activity are described in the following items 1) to 7). All of the items described in 1) to 7) are included in the invention. In the following
20 items 1) to 7), the "joint disease aggrecanase" is described as "protein".

1) Production method of protein gene

a) First production method - a method which uses PCR

A mRNA sample is extracted from a human cell or
25 tissue having the ability to produce the novel protein of the invention. Next, using this mRNA as the template, two

primers interposing the mRNA or a part of mRNA of the novel protein are prepared. Full-length cDNA or a part thereof corresponding to the novel protein can be obtained by modifying denature temperature, denaturing agent adding condition and the like and carrying out a reverse transcriptase-polymerase chain reaction (to be referred to as RT-PCR hereinafter) suited for a respective protein comprising a part of the amino acid sequence represented by SEQ ID NO:1 of the invention. Alternatively, full-length cDNA or a part thereof corresponding to the novel protein can be obtained by carrying out a polymerase chain reaction (to be referred to as RT-PCR hereinafter), by using cDNA prepared using reverse transcriptase from mRNA which is extracted from a human cell or tissue having the ability to produce the novel protein of the invention, or a commercially available cDNA preparation derived from a human cell or tissue, as the template. Thereafter, the novel protein can be produced by integrating the thus obtained full-length cDNA or a part thereof corresponding to the novel protein into an appropriate expression vector and expressing it in a host cell.

Firstly, mRNA comprising a sequence coding for the protease is extracted from a human cell or tissue having the ability to produce the novel protein of the invention by a known method. As the extraction method, a guanidine thiocyanate hot phenol method, a guanidine thiocyanate-

guanidine hydrochloride method and the like can be exemplified, but a guanidine thiocyanate cesium chloride method can be preferably cited. The cell or tissue having the ability to produce this protease can be specified by, e.g., northern blot technique using a gene or a part thereof having a nucleotide sequence coding for the protease or western blot technique using an antibody specific for the protease.

Purification of mRNA can be carried out in accordance with a usual method, for example, it can be purified by binding it to an oligo(dT) cellulose column and then eluting it. Alternatively, a commercially available extracted and purified mRNA may be used without extracting the mRNA.

Subsequently, single-strand cDNA is synthesized by carrying out reverse transcriptase reaction of the purified mRNA in the presence of random primers, oligo(dT) primers or custom-synthesized primers. Using two primers interposing a part of the gene of interest, the thus obtained single-strand cDNA is subjected to PCR to amplify the novel protein DNA of interest. Alternatively, a commercially available cDNA preparation may be used without synthesizing the cDNA. The thus obtained DNA is fractionated by a means such as agarose gel electrophoresis or the like. If desired, a DNA fragment of interest can be

obtained by digesting this DNA with restriction enzymes and the like and then ligating the digested fragments.

b) Second production method

In addition to the above production method, the gene
5 of the invention can be produced using conventional genetic engineering techniques. Firstly, single-strand cDNA is synthesized using reverse transcriptase and using the mRNA obtained by the above method as the template and then double-strand cDNA is synthesized from this single-strand
10 cDNA. As the method, the S1 nuclease method (Efstratiadis, A. et al., *Cell*, 7, 279 - 288, 1976), Land method (Land, H. et al., *Nucleic Acids Res.*, 9, 2251 - 2266, 1981), O. Joon Yoo method (Yoo, O.J. et al., *Proc. Natl. Acad. Sci. USA*, 79, 1049 - 1053, 1983), the Okayama-Berg method (Okayama, H. and Berg, P., *Mol. Cell. Biol.*, 2, 161 - 170, 1982) and
15 the like can be exemplified.

Next, an *Escherichia coli* strain such as DH5 α strain, HB101 strain, JM109 strain or the like is transformed by introducing a recombinant plasmid obtained
20 by the aforementioned method, and a resulting recombinant can be selected using the resistance for a drug such as tetracycline, ampicillin, kanamycin or the like as a marker. Transformation of a host cell, for example, when the host cell is *E. coli*, can be carried out by Hanahan's
25 method (Hanahan, D.J., *Mol. Biol.*, 166, 557 - 580, 1983), namely, by adding the recombinant DNA to competent cells

prepared in the coexistence of CaCl_2 and MgCl_2 or RbCl . As a matter of course, commercially available competent cells can also be used. In this connection, in addition to a plasmid, a phage vector such as a lambda system can also be used as a vector.

Regarding the method for selecting DNA of the novel protein of interest from the thus obtained transformants, various methods shown below can for example be employed.

(i) A screening method which uses a synthetic oligonucleotide probe

An oligonucleotide corresponding to whole or a part of the novel protein of the invention is synthesized (in this case, it may be either a nucleotide sequence derived by using the codon usage or a combination of two or more possible nucleotide sequences, and in the latter case, the number of their kinds can be reduced by including inosine), this is hybridized as a probe (after labeling with ^{32}P or ^{33}P) with a nitrocellulose filter or nylon filter on which DNA samples of the transformants are denatured and immobilized, and then the thus obtained positive strains are screened and selected.

(ii) A screening method which uses a probe prepared by polymerase chain reaction

Oligonucleotides of a sense primer and an antisense primer corresponding to a part of the novel protein of the invention are synthesized and polymerase chain reaction

(Saiki, R.K. et al., *Science*, 239, 487 - 491, 1988) is carried out using these primers, thereby effecting amplification of a DNA fragment coding for whole or a part of the novel protein of interest. As the template DNA to be used, cDNA synthesized by reverse transcription reaction from mRNA of cells producing the novel protein or genomic DNA can be used. The thus prepared DNA fragment is labeled with ^{32}P or ^{33}P and used as the probe to carry out colony hybridization or plaque hybridization to select the clone of interest.

(iii) A screening method in which the novel protein is produced by other animal cells

A transformant is cultured to amplify a gene, an animal cell is transfected with the gene (in this case, the vector may be either an autonomously replicating plasmid comprising a transcription promoter region or a plasmid which can be integrated into chromosome of the animal cell), and the protein encoded by the gene is produced in the extracellular moiety. By detecting the novel protein using an antibody specific for the novel protein of the invention, a strain comprising cDNA which encodes the novel protein of interest is selected from the original transformants.

(iv) A selection method which uses an antibody specific for the novel protein of the invention

By integrating cDNA into an expression vector in advance, proteins are produced in culture supernatants, inside the cells or on the surface of cells of transformants, and the strain of interest is selected by detecting the novel protein producing strain of interest using an antibody specific for the novel protein of the invention and a secondary antibody against this antibody.

(v) A method which uses a selective hybridization-translation system

Samples of cDNA obtained from transformants are blotted on a nitrocellulose filter or the like, mRNA prepared from the novel protein producing cells of the invention is hybridized therewith, and then the mRNA hybridized to the cDNA is dissociated and recovered. The thus recovered mRNA samples are translated into proteins in a protein translation system, e.g., a system in which they are injected into oocyte of *Xenopus* or a cell free system such as rabbit reticulocyte lysate, wheat germ or the like. The strain of interest is selected by detecting it using an antibody against the novel protein of the invention.

The method for collecting DNA coding for the novel protein of the invention from the thus obtained transformant of interest can be carried out in accordance with gene manipulation experiment manuals such as of a

known method (Sambrook, J. et al., "Molecular Cloning - A Laboratory Manual", Cold Spring Harbor Laboratory, NY, 1989) and the like. For example, it can be achieved by separating a fraction corresponding to plasmid DNA from
5 cells and then cutting out the cDNA region from the plasmid DNA.

c) Third production method

The novel protein gene of the invention can also be produced by connecting DNA fragments produced by a chemical
10 synthesis method. Each DNA can be synthesized using a DNA synthesizing machine [e.g., Oligo 1000M DNA Synthesizer (mfd. by Beckman), 394 DNA/RNA Synthesizer (mfd. by Applied Biosystems) or the like].

d) Fourth production method

15 The novel protein gene of the invention can also be produced based on the information on the novel protein, for example, by chemical synthesis of nucleic acids in accordance with a conventional method such as phosphite triester method (Hunkapiller, M. et al., *Nature*, 10, 105 -
20 111, 1984) or the like. In this connection, codons for desired amino acids are well known, can be selected optionally and can be determined in accordance with a conventional method (Crantham, R. et al., *Nucleic Acids Res.*, 9, r43 - r74, 1981), taking codon usage of the host
25 to be used into consideration. In addition, partial modification of codons of these nucleotide sequences can be

carried out in the usual way in accordance with the site specific mutagenesis (Mark, D.F. et al., Proc. Natl. Acad. Sci. USA, 81, 5662 - 5666, 1984) or the like which uses primers comprised of synthetic oligonucleotides which
5 encode the desired modification.

Determination of sequences of DNA obtained by the above methods a) to d) can be carried out for example by Maxam-Gilbert chemical modification method (Maxam, A.M. and Gilbert, W., "Methods in Enzymology", 65, 499 - 559, 1980),
10 dideoxy nucleotide chain termination method (Messing, J. and Vieira, J., *Gene*, 19, 269 - 276, 1982) and the like.

2) Methods for the production of the vector of the invention, the host cell of the invention and the recombinant protein of the invention

15 The thus isolated fragment containing the gene coding for the novel protein of the invention can be transformed into eucaryotic or procaryotic host cells by again integrating it into an appropriate vector DNA. In addition, it is possible to express the gene in respective
20 host cells by introducing an appropriate promoter and a sequence concerned in the gene expression into these vectors.

For example, the eucaryotic host cells include cells of a vertebrate, an insect, yeast and the like, and COS
25 cell as a monkey cell (Gluzman, Y., *Cell*, 23, 175 - 182, 1081), a dihydrofolate reductase deficient strain of

Chinese hamster ovary cell (CHO) (Urlaub, G. and Chasin,
L.A., *Proc. Natl. Acad. Sci. USA*, 77, 4216 - 4220, 1980),
human fetal kidney-derived HEK293 cell, 293-EBNA cell in
which Epstein-Barr virus EBNA-1 gene is introduced into the
5 same cell (mfd. by Invitrogen) and the like are frequently
used as the vertebrate cells, though limited thereto.

As the expression vector for vertebrate cells, a
vector having a promoter, a RNA splicing site, a
polyadenylation site, a transcription termination
10 sequence and the like generally positioned upstream of the
gene to be expressed can be used, and it may further have a
replication origin as occasion demands. Examples of the
expression vector include pSV2dhfr having SV40 early
promoter (Subramani, S. et al., *Mol. Cell. Biol.*, 1, 854 -
15 864, 1981), pEF-BOS having human elongation factor promoter
(Mizushima, S. and Nagata, S., *Nucleic Acids Res.*, 18,
5322, 1990), pCEP4 having cytomegalovirus promoter (mfd. by
Invitrogen) and the like, though not limited thereto.

In the case of the use of COS cell as the host cell,
20 an expression vector which has SV40 replication origin, can
perform autonomous replication in COS cell and has a
transcription promoter, a transcription termination signal
and an RNA splicing site can be used, and its examples
include pME18S (Maruyama, K. and Takebe, Y., *Med. Immunol.*,
25 20, 27 - 32, 1990), pEF-BOS (Mizushima, S. and Nagata, S.,
Nucleic Acids Res., 18, 5322, 1990), pCDM8 (Seed, B.,

Nature, 329, 840 - 842, 1987) and the like. The expression vector can be incorporated into COS cell by a DEAE-dextran method (Luthman, H. and Magnusson, G., *Nucleic Acids Res.*, 11, 1295 - 1308, 1983), a calcium phosphate-DNA co-precipitation method (Graham, F.L. and van der Ed, A.J., *Virology*, 52, 456 - 457, 1973), a method which uses FuGENETM6 Transfection Reagent (mfd. by Boehringer Mannheim), an electroporation method (Neumann, E. et al., *EMBO J.*, 1, 841 - 845, 1982) and the like, thus enabling to obtain a desired transformant cell.

Also, when CHO cell is used as the host cell, a transformant cell which can stably produce the novel protein can be obtained by co-transfecting a vector capable of expressing neo gene which functions as a G418 resistance marker, such as pRSVneo (Sambrook, J. et al., "Molecular Cloning - A Laboratory Manual", Cold Spring Harbor Laboratory, NY, 1989), pSV2-neo (Southern, P.J. and Berg, P., *J. Mol. Appl. Genet.*, 1, 327 - 341, 1982) or the like, together with an expression vector and then selecting a G418-resistant colony. Also, when 293-EBNA cell is used as the host cell, a desired transformant cell can be obtained using an expression vector which has Epstein-Barr virus replication origin and can perform autonomous replication in the 293-EBNA cell, such as pCEP4 (mfd. by Invitrogen) or the like.

The thus obtained transformant cell of interest can be cultured in accordance with a conventional method, and the novel protein of the invention is produced in extracellular moiety by this culturing. As the medium to be used in the culturing, various conventionally used media can be optionally selected depending on the host cell employed. In the case of, for example, the COS cell, a medium such as a RPMI-1640 medium, Dulbecco's modified Eagle's minimum essential medium (DMEM) or the like which may be supplemented, as occasion demands, with a serum component such as fetal bovine serum (FBS) or the like may be used. Also, in the case of the 293-EBNA cell, a medium such as Dulbecco's modified Eagle's minimum essential medium (DMEM) or the like supplemented with a serum component such as fetal bovine serum (FBS) or the like and further supplemented with G418 may be used.

The novel protein of the invention thus produced in the extracellular moiety of the transformant cell can be separated and purified by various known separation techniques making use of physical characteristics, biochemical characteristics and the like of the novel protein. Illustrative examples of such techniques include treatment of a culture broth containing the novel protein with a usual protein precipitant, ultrafiltration, various types of liquid chromatography such as molecular sieve chromatography (gel filtration), adsorption chromatography,

ion exchange chromatography, affinity chromatography, high performance liquid chromatography (HPLC) and the like, dialysis and combinations thereof.

When the novel protein of the invention is expressed after its in frame fusion with a marker sequence, expression verification, purification and the like of the novel protein become possible. Examples of the marker sequence include FLAG epitope, Hexa-Histidine tag, Hemagglutinin tag, myc epitope and the like. Also, when a specific amino acid sequence recognizable by proteases such as enterokinase, factor Xa, thrombin and the like is inserted between a marker sequence and the novel protein, the marker sequence moiety can be cut off and removed by these proteases.

3) Method for detecting the aggrecanase activity of the protein of the invention

The aggrecanase activity of the protein of the invention can be detected by mixing the joint disease aggrecanase of the invention with each of the substrates described below in an appropriate buffer solution, allowing them to react with each other and then detecting the reaction product by a method suited for each substrate.

As the substrate, aggrecan purified from a cartilage or tissue of human or other animal, aggrecan obtained by genetic recombination, commercially available aggrecan (mfd. by Seikagaku Kogyo) or a partial protein thereof can

be used. The aggrecanase activity can be measured by allowing these substrates to react with a cell or tissue culture broth, a cell or tissue extract or a (partially) purified sample containing a protease to be tested, and then detecting a fragment cleaved off at the site between Glu³⁷³-Ala³⁷⁴. The fragment cleaved off at the site between Glu³⁷³-Ala³⁷⁴ can be detected by a method in which an N-terminal sequence or a C-terminal sequence of the digested fragment is determined in accordance with a conventional method, or more conveniently, by an immunological method such as an ELISA (enzyme-linked immunosorbent assay) which uses an anti-neoepitope antibody capable of specifically recognizing C-terminal NITGE³⁷³ and N-terminal ³⁷⁴ARGSV generated by the cutting between Glu³⁷³-Ala³⁷⁴, a western blotting or the like. Preferably, it can be carried out by the methods described in Examples 7 and 9.

4) Method for preparing antibody which reacts with the novel protein of the invention

The antibody which reacts with the novel protein of the invention, such as a polyclonal antibody or a monoclonal antibody, can be obtained by directly administering the novel protein or a fragment of the novel protein to various animals. It can also be obtained by a DNA vaccine method (Raz, E. et al., *Proc. Natl. Acad. Sci. USA*, 91, 9519 - 9523, 1994; Donnelly, J.J. et al., *J. Infect. Dis.*, 173, 314 - 320, 1996) using a plasmid into

which a gene coding for the novel protein of the invention is introduced.

5 A polyclonal antibody is produced from a serum or egg of an animal such as rabbit, rat, goat, domestic fowl or the like which is sensitized by immunizing the animal with the novel protein or a fragment thereof emulsified in an appropriate adjuvant such as complete Freund's adjuvant by its peritoneal, subcutaneous, intravenous or the like injection. The thus produced polyclonal antibody can be
10 separated and purified by usual protein isolation and purification techniques, and examples of the usual protein isolation and purification techniques include centrifugation, dialysis, salting out with ammonium sulfate and a chromatography using DEAE-cellulose, hydroxyapatite,
15 protein A agarose or the like.

A monoclonal antibody can be produced easily by those skilled in the art by the cell fusion method of Kohler and Milstein (Kohler, G. and Milstein, C., *Nature*, 256, 495 - 497, 1975).

20 That is, mouse is immunized by emulsifying the novel protein of the invention or a fragment thereof in an appropriate adjuvant such as complete Freund's adjuvant and inoculating the emulsion several times at intervals of a few weeks by its peritoneal, subcutaneous, intravenous or
25 the like injection. After the final immunization, spleen

cells are taken out and fused with myeloma cells to prepare hybridomas.

As the myeloma cells for obtaining hybridomas, a myeloma cell having a marker (e.g., hypoxanthine-guanine phosphoribosyl transferase deletion, thymidine kinase deletion or the like), such as a mouse myeloma cell strain P3X63Ag8.U1, is used. Also, polyethylene glycol is used as the fusing agent. As the medium for preparing hybridomas, Eagle's minimum essential medium, Dulbecco's minimum essential medium, RPMI1640 or the like usually used medium is used by optionally supplementing it with 10 to 30% fetal bovine serum. The fused strains are selected by the HAT selection method. Screening of hybridomas is carried out using culture supernatants by ELISA, immunological tissue staining or the like well known method or by the aforementioned screening method, and a clone of hybridoma which secretes the antibody of interest is selected. Also, monoclonal nature of the hybridoma is confirmed by repeating subcloning by limiting dilution. By culturing the thus obtained hybridoma in a medium for several days or in the abdominal cavity of a pristane-pretreated BALB/c mouse for 10 to 20 days, the antibody is produced in a purification-possible amount. The thus produced monoclonal antibody can be separated and purified from the culture supernatant or ascitic fluid by usual protein isolation purification techniques.

Active antibody fragments containing a part of the antibody, such as $F(ab')_2$, Fab, Fab' and Fv, can be obtained by digesting the thus separated and purified antibody with a proteolytic enzyme such as pepsin, papain or the like in the conventional way and then separating and purifying the fragments by usual protein isolation purification techniques.

Furthermore, it is possible to obtain the antibody which reacts with the novel protein of the invention as single chain Fv or Fab by the methods of Clackson et al. and Zebedee et al. (Clackson, T. et al., *Nature*, 352, 624 - 628, 1991; Zebedee, S. et al., *Proc. Natl. Acad. Sci. USA*, 89, 3175 - 3179, 1992). In addition, it is possible to obtain a human antibody by immunizing a transgenic mouse in which a mouse antibody gene is replaced by a human antibody gene (Lonberg, N. et al., *Nature*, 368, 856 - 859, 1994).

5) Method for screening a substance which inhibits the aggrecanase activity of the "joint disease aggrecanase" of the invention

This can be screened by a similar method of the aggrecanase activity detection method described in 3). Also, the ELISA or the like method exemplified in Example 10-2 can be used, in which added aggrecan, recombinant aggrecan, commercially available aggrecan or a partial protein thereof which disappears or decreases by its degradation when allowed to react with the novel protein of

the invention is measured using an antibody which specifically recognizes polypeptides of the N-terminal side and C-terminal side moieties of the region cleaved off with aggrecanase. Also useful is a method in which the novel

5 protein of the invention is allowed to react with a recombinant aggrecan in which FLAG tag is added to the N-terminal, and His tag to the C-terminal, as exemplified in Example 7-1, and the added recombinant aggrecan disappeared or decreased by its degradation is measured by ELISA or the

10 like method using an anti-FLAG tag and anti-His tag antibodies. The tags in this case are not limited to FLAG tag and His tag, and the recombinant aggrecan is not limited to Example 7-1 and may be a partial protein or modified protein of aggrecan which is cleaved off at the

15 aggrecanase digesting site by this protein. Regarding the substance to be tested for its aggrecanase activity,

compounds or peptides which are generally known to have metalloprotease inhibition activity but their activities to inhibit the aggrecanase activity of the novel protein are

20 unclear, or various known compounds and peptides, compounds synthesized using combinatorial chemistry techniques (Terrett, N.K. et al., *Tetrahedron*, 51, 8135 - 8137, 1995) or general synthesis techniques and random peptides prepared by applying a phage display method (Felici, F. et

25 al., *J. Mol. Biol.*, 222, 301 - 310, 1991) and the like, can be used as the substance to be tested. In addition,

extracts and culture supernatants of microorganisms,
natural components derived from plants and marine
organisms, animal tissue extracts and the like are also
become objects of the screening. Or possibly, compounds or
5 peptides prepared by chemically or biologically structure-
modified from compounds or peptides selected by the
screening method of the invention can also be used.

For the screening of substances which inhibit the
aggrecanase activity of the novel protein of the invention
10 (compounds, peptides, antibodies and antibody fragments),
any substance which becomes the substrate of the novel
protein of the invention or of a partial peptide thereof
can be used, and the substrates described in the
aforementioned item 3) are desirable.

15 6) Method for detecting degradation and release of
proteoglycan

A method exemplified in Example 11-2 in which $^{35}\text{SO}_4^{2-}$
is used as a tracer, a method in which a proteoglycan
antibody is used, a method in which degraded fragments are
20 detected by gel filtration (Methods in Cartilage Research,
Academic Press, 1990; Joint Cartilage Degradation, Marcel
Dekker, Inc., 1993), a colorimetric method (Goldberg R.L.
and Kolibas L.M., *Connect. Tissue Res.*, 24, 265 - 275,
1990) which uses 1,9-dimethylmethylene blue (DMMB) and the
25 like are used for the detection and measurement of the

degradation and release of cartilage proteoglycan, though not limited thereto.

7) Method for screening a substance which inhibits promoter activity of the invention

5 In screening a substance which inhibits the promoter activity of the invention, a method in which a reporter gene plasmid containing the sequences shown in Example 13 (SEQ ID NOs:24 and 31) and partial sequences thereof is used is convenient as the method for detecting the promoter
10 activity. The reporter gene means a gene coding for a protein which can be determined by usual means (e.g., determination methods well known to those skilled in the art such as measurement of enzyme activities and the like), and chloramphenicol acetyltransferase, luciferase, β -
15 galactosidase and alkaline phosphatase genes are frequently used, though not limited thereto. Regarding a vector for constructing a reporter gene plasmid, there is no limitation and commercially available plasmid vectors such as pGV-B2 (mfd. by Toyo Ink), pSEAP2-Basic (mfd. by
20 Clontech) and the like can be used. By constructing a reporter gene plasmid in which the sequence is inserted in the forward direction into upstream of the reporter gene of these vectors and measuring amount of the reporter protein expressed in cells transformed with this plasmid, by a
25 method suited for respective case, the presence and strength of the promoter activity of the sequence can be

known, and action of a substance to be tested upon this promoter activity can be detected by adding the substance to be tested to a culture broth of the transformed cells.

For the screening of substances which inhibit the promoter activity possessed by the sequence of the Sequence ID No. of the invention and a partial sequence thereof (compounds, peptides, antibodies and antibody fragments), a method similar to the aforementioned promoter activity detection method can be used. Regarding the substance to be tested, compounds or peptides which are generally known to have promoter inhibition activity but their activities to inhibit the promoter activity possessed by the sequences of SEQ ID NOs:24 and 31 and partial sequences thereof are unclear or various known compounds and peptides, compounds synthesized using combinatorial chemistry techniques (Terrett, N.K. et al., *Tetrahedron*, 51, 8135 - 8137, 1995) or general synthesis techniques and random peptides, antibodies and antibody fragments prepared by applying a phage display method (Felici, F. et al., *J. Mol. Biol.*, 222, 301 - 310, 1991) can be used. In addition, extracts and culture supernatants of microorganisms, natural components derived from plants and marine organisms, animal tissue extracts and the like are also become the object of the screening. Or possibly, compounds or peptides prepared by chemically or biologically structure-modified from

compounds or peptides selected by the screening method of the invention can also be used.

A medicament which comprises as the active ingredient a substance which inhibits the aggrecanase activity of the "joint disease aggrecanase" and is selected by the aforementioned screening method (a compound, peptide, antibody or antibody fragment) is included in the invention, and a pharmaceutical composition for inhibiting degradation of proteoglycans is particularly desirable as the medicament. Examples of the substance which significantly inhibits activity of the "joint disease aggrecanase" include N^{α} -[2-(1-hydroxycarbamoyl-2-sulfanylethyl)-4-methylpentanoyl]-N,O-dimethyltyrosineamide (to be referred to as compound A hereinafter), N^{α} -[2-(1-hydroxycarbamoyl-2-sulfanylethyl)-4-methylpentanoyl]-N-methylphenylalanineamide (to be referred to as compound B hereinafter), N^{α} -[2-(1-hydroxycarbamoyl-2-phenylsulfanylethyl)-4-methylpentanoyl]-N,O-dimethyltyrosineamide (to be referred to as compound C hereinafter), N^{α} -[2-(1-hydroxycarbamoyl-2-methylsulfanylethyl)-4-methylpentanoyl]-N,O-dimethyltyrosineamide (to be referred to as compound D hereinafter) and the like selected by the screening system shown in Example 10-2. The compound A, compound B, compound C and compound D are compounds included in the

claims of WO 90/05719, but not only medicaments comprising these compounds as the active ingredient but also all medicaments which comprises substances capable of significantly inhibiting the aggrecanase activity of the "joint disease aggrecanase" are included in the invention. In this connection, the compound A, compound B, compound C and compound D are compounds can be synthesized in the same manner as the compounds disclosed in WO 90/05719 in accordance with the production methods disclosed in WO 90/05719.

The medicament comprising a substance (a compound, peptide, antibody or antibody fragment) which significantly inhibits the aggrecanase activity of the "joint disease aggrecanase" of the invention as the active ingredient can be prepared using carriers, fillers and other additives usually used for their preparation, in response to each type of the active ingredient.

Examples of its administration include oral administration using tablets, pills, capsules, granules, fine subtilaes, powders, oral solutions and the like and parenteral administration using intravenous, intramuscular, intraarticular and the like injections, suppositories, percutaneous preparations, transmucosal preparations and the like. Particularly in the case of peptides which are digested in the stomach, parenteral administration such as intravenous injection or the like is desirable.

In the solid composition for use in the oral administration according to the present invention, one or more active substances are mixed with at least one inert diluent such as lactose, mannitol, glucose, microcrystalline cellulose, hydroxypropylcellulose, starch, polyvinyl pyrrolidone, aluminum magnesium silicate or the like. In the usual way, the composition may contain other additives than the inert diluent, such as a lubricant, a disintegrating agent, a stabilizing agent, a solubilizing or solubilization assisting agent or the like. If necessary, tablets or pills may be coated with a sugar or a film of a gastric or enteric substance.

The liquid composition for oral administration includes emulsions, solutions, suspensions, syrups and elixirs and contains a generally used inert diluent such as purified water or ethanol. In addition to the inert diluent, this composition may contain auxiliary agents such as a moistening agent, a suspending agent, a sweetener, an aromatic agent and an antiseptic agent.

The injections for parenteral administration includes aseptic aqueous or non-aqueous solutions, suspensions and emulsions. Examples of the diluent for use in the aqueous solutions and suspensions include distilled water for injection, physiological saline and the like. Examples of the diluent for use in the non-aqueous solutions and suspensions include propylene glycol, polyethylene glycol,

plant oil (e.g., olive oil or the like), alcohol (e.g., ethanol), Polysorbate 80 and the like. Such a composition may further contain a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent, a
5 solubilizing or solubilization assisting agent, an antiseptic and the like. These compositions are sterilized by filtration through a bacteria retaining filter, blending of a germicide or irradiation. Alternatively, they may be used by firstly making into sterile solid compositions and
10 dissolving them in sterile water or a sterile solvent for injection use prior to their use.

The clinical dose is optionally decided by taking into consideration strength of activity of the active ingredient selected by the aforementioned screening method,
15 symptoms, age, sex and the like of each patient to be treated.

For example, the dose is usually from about 0.1 to 1,000 mg, preferably from 0.1 to 100 mg, per day per adult (as 60 kg in body weight) in the case of oral
20 administration. In the case of parenteral administration, it is from about 0.01 to 1,000 mg, preferably from 0.01 to 100 mg, per day in the form of injections.

Brief Description of the Drawings

25 Fig. 1 is a photograph showing a result of the expression of MDTS6TSP1 in an animal cell strain using an

ECL western blotting detection system, obtained in Example 6.

Fig. 2 is a photograph showing a result of the detection of the activity of MDTS6TSP1 to degrade a recombinant aggrecan G1G2 using an ECL western blotting detection system, obtained in Example 7-2.

Fig. 3 is a photograph showing a result of the analysis of a recombinant aggrecan G1G2 degraded with MDTS6TSP1, by an anti-aggrecanase neoepitope antibody, using a western blotting detection system, obtained in Example 7-3.

Fig. 4 is an electrophoresis pattern photograph showing a result of the examination of MDTS6 mRNA expression induction by IL-1 β , obtained in Example 8.

Fig. 5 is a photograph showing a result of the detection of degradation of natural type aggrecan by MDTS6 protein, by an anti-aggrecanase neoepitope antibody, using a western blotting detection system, obtained in Example 9-2.

Fig. 6 is a graph showing a result of the detection of release of proteoglycan from rabbit knee joint primary culture cells by all-trans retinoic acid and IL-1 β , obtained in Example 11-2.

Fig. 7 is an electrophoresis pattern photograph showing a result of the analysis of changes in gene expression of MDTS6 by RT-PCR when rabbit knee joint

primary culture cells are treated with all-trans retinoic acid and IL-1 β , obtained in Example 11-3.

Fig. 8 is a graph showing that degradation and release of proteoglycan from rabbit knee joint primary culture cells by all-trans retinoic acid are inhibited by the compound A and compound B, obtained in Example 12.

Best Mode for Carrying Out the Invention

The following describes the invention more illustratively.

Unless otherwise noted, experiments were carried out in accordance with gene manipulation experiment manuals such as of a known method (Sambrook, J. et al., "Molecular Cloning - A Laboratory Manual", Cold Spring Harbor Laboratory, NY, 1989) and the like, but the invention is not limited to the Examples.

(Example 1) Discovery of partial sequence of a novel ADAMTS gene MDTS6

A human brain cDNA library strictly fractionated by the size of insertion sequences was constructed as shown in a reference (Ohara O. et al., *DNA Res.*, 4, 53 - 59, 1997). Size distribution of cDNA fragments in these sub-libraries was from 3 kbp to 8 kbp. By deciphering 5'- and 3'-end sequences of clones constituting this library, an in-house EST data bank was constructed. A partial sequence of MDTS6 was obtained from this.

(Example 2) Determination of full-length ORF sequence
of MDTS6

By determining sequences of MDTS6 cDNA clones, a
sequence of from the 832nd position to the 2853rd position
5 of SEQ ID NO:2 was obtained. The sequence of from the 1st
position to the 831st position of SEQ ID NO:2 was obtained
by repeating RACE (Rapid Amplification of cDNA Ends) using
human brain and human placenta Marathon-Ready™ cDNA
manufactured by Clontech as the template and LA-Taq™ (mfd.
10 by Takara Shuzo) as the DNA polymerase. As a result, it
was revealed that the full-length MDTS6 was a novel protein
composed of 950 amino acids as shown in SEQ ID NO:1. Its
domain structure was composed of a secretion signal
sequence, a pro region, a furin protease recognition
15 sequence, a metalloprotease domain, a disintegrin domain, a
thrombospondin type I repeat sequence (to be referred to as
TSP-1 repeat sequence hereinafter), a domain rich in Cys
residue, an intermediate region and two TSP-1 repeat
sequences, in order from the N-terminus, and it was a
20 molecule belonging to the ADAMTS family (Kuno, K. et al.,
J. Biol. Chem., 272, 556 - 562, 1997; Tang, B.L. et al.,
FEBS Lett., 445, 223 - 225, 1999).

(Example 3) Preparation of C-terminal FLAG addition
type expression vector

25 An EBNA1 expression unit-removed expression vector
pCEP4d was constructed by digesting pCEP4 (mfd. by

Invitrogen) with restriction enzymes *ClaI* and *NsiI*, blunt-
ending the resulting fragments and then carrying out their
autonomous ligation. This vector was digested with
restriction enzymes *NheI* and *BamHI* and extracted from an
5 agarose gel to obtain a fragment of about 7.7 kbp, and a
double strand of oligonucleotide obtained by annealing a
nucleic acid shown by SEQ ID NO:3 and a nucleic acid shown
by SEQ ID NO:4 was inserted into the fragment to select a
clone having the planned sequence which was named pCEP4d-
10 FLAG. Using this vector as the template and oligoDNA shown
by SEQ ID NO:5 and oligoDNA shown by SEQ ID NO:6 as
primers, PCR was carried out using PyroBest™ DNA
polymerase. The thus generated DNA fragment of about 0.4
kbp was digested with a restriction enzyme *SpeI* and
15 inserted into pCEP4d-FLAG (about 7.7 kbp) which had been
digested with *XbaI*, and a clone in which *XbaI*, *NheI*, *NotI*
and *BamHI* recognition sequence cloning sites and FLAG tag
were arranged in that order from the promoter as intended
was selected, thereby completing pCEP4dE2-FLAG.

20 (Example 4) Construction of MDTS6 truncated protein
(MDTS6TSP1) expression plasmid

A plasmid was constructed in the following manner for
use in expressing a sequence of from the 1st position to
the 583rd position of SEQ ID NO:1 (a moiety corresponding
25 to a region containing the TSP1 repeat sequence from the N-
terminus of MDTS6 (to be referred to as MDTS6TSP1

hereinafter)) as a protein in which FLAG was added to the C-terminus.

Firstly, a gene of from the 1st position to the 1749th position of SEQ ID NO:2 was obtained by PCR. Using oligoDNA sequences represented by SEQ ID NO:7 and SEQ ID NO:8 as primers, human placenta Marathon-Ready™ cDNA (mfd. by Clontech) as the template and LA-Taq™ (mfd. by Takara Shuzo) as DNA polymerase, a cycle of 98°C for 10 seconds and 68°C for 2 minutes was repeated 10 times after heating at 94°C for 1 minutes. Using a DNA solution prepared by 50 times-diluting this reaction solution as the template and using PyroBest™ DNA polymerase, PCR was carried out under a condition of 94°C for 2 minutes, 40 repetitions of a cycle of 98°C for 10 seconds, 66°C for 30 seconds and 74°C for 4 minutes and subsequent 72°C for 10 minutes. The thus generated fragment of interest in which XbaI recognition sequence and Kozak sequence were added to the 5' side, and NotI recognition sequence to the 3' side, was subcloned into PCR-Blunt to confirm the sequence and then digested with restriction enzymes XbaI and NotI and inserted into the XbaI-NotI site of pCEP4dE2-FLAG to complete pCEP-MDTS6TSP1-FLAG.

(Example 5) Construction of MDTS6 full-length protein expression plasmid

A plasmid was constructed in the following manner for use in expressing a sequence of from the 1st position to

the 950th position of SEQ ID NO:1 as a protein in which FLAG was added to the C-terminus.

Firstly, a gene of from the 1534th position to the 2850th position of SEQ ID NO:2 was obtained by PCR.

5 Illustratively, using oligoDNA sequences represented by SEQ ID NO:9 and SEQ ID NO:10 as primers, the plasmid DNA of EST clone as the template and PyroBest™ DNA polymerase as DNA polymerase, a cycle of 98°C for 10 seconds, 50°C for 15 seconds and 72°C for 2 minutes was repeated 20 times after
10 heating at 94°C for 1 minutes, followed by 7 minutes of reaction at 72°C. In this connection, it was able to generate the fragment of interest by carrying out PCR using human placenta Marathon-Ready™ cDNA (mfd. by Clontech) as the template, instead of using the plasmid DNA of EST clone
15 as the template, and using oligoDNA sequences represented by SEQ ID NO:9 and SEQ ID NO:10 as primers under a condition of 94°C for 2 minutes, 40 repetitions of a cycle of 98°C for 10 seconds and 68°C for 2 minutes and subsequent 72°C for 7 minutes. The thus generated fragment
20 of interest in which NotI recognition sequence was added to the 3' side was subcloned into PCR-Blunt to confirm the sequence and used as pCRB-MDTS6-3H.

Making use of the presence of a BamHI recognition sequence in a sequence of from the 1566th position to the
25 1571st position of SEQ ID NO:2, pCEP-MDTS6TSP1-FLAG was digested with restriction enzymes XbaI and BamHI, and the

thus generated DNA fragment of about 1.6 kbp was connected to a DNA fragment of about 1.3 kbp generated by digesting pCRB-MDTS6-3H with *Bam*HI and *Not*I and inserted into the *Xba*I-*Not*I site of pCEP4dE2-FLAG to complete pCEP-MDTS6F-FLAG.

(Example 6) Expression of MDTS6TSP1 and MDTS6 full-length proteins by animal cell strain

The expression plasmid prepared in Example 4 using pCEP4dE2-FLAG as the backbone was introduced into HEK293-EBNA cell (mfd. by Invitrogen) using FuGENETM6 Transfection Reagent (mfd. by Boehringer Mannheim) in accordance with the attached instructions. After introduction of the plasmid, the presence of the protein of interest in a culture supernatant obtained by 1 to 2 days of culturing was confirmed by western blotting using an antibody against FLAG tag added to the C-terminus (a mouse anti-FLAG monoclonal antibody (M2; mfd. by Sigma)). That is, the culture supernatant was subjected to electrophoresis using SDS/10% to 20% acrylamide gel (mfd. by Daiichi Pure Chemicals) and then transferred on a PVDF membrane using a blotting apparatus. The PVDF membrane after the transfer was subjected to blocking by adding Block Ace (mfd. by Dainippon Pharmaceutical) and then allowed to react with the mouse anti-FLAG monoclonal antibody (M2; mfd. by Sigma) and a horseradish peroxidase-labeled rabbit anti-mouse IgG polyclonal antibody (mfd. by Zymed or TAGO) in that order.

Alternatively, after the blocking, it was allowed to react with biotinylated M2 antibody (mfd. by Sigma) and a streptoavidine-horseradish peroxidase conjugate (mfd. by Amersham) in that order. After the reaction, expression of the protein was confirmed using an ECL western blotting detection system (mfd. by Amersham Pharmacia) (Fig. 1). Molecular weight of the expressed MDTS6TSP1 protein was smaller than the value calculated from the amino acid sequence by a factor of about 23 K. Making use of the fact that FLAG tag is added to the C-terminus of MDTS6TSP1 protein expressed by the HEK293-EBNA cell as described in the foregoing, MDTS6TSP1 protein was affinity-purified by the method of Example 7-1 and then transferred on a PVDF membrane, and the N-terminal sequence of MDTS6TSP1 protein stained with Ponceau S was determined by analyzing with Type 494 Peptide Sequencer manufactured by ABI. As a result, it was shown that it starts from the 213th position Phe of SEQ ID NO:1 and, similar to the case of other ADAMTS molecules, becomes mature protein (from 213th position to 583rd position of SEQ ID NO:1) by being cleaved at the furin protease recognition sequence existing between the pro region and metalloprotease domain. Also, the MDTS6 full-length protein was obtained in the same manner as the case of the above MDTS6TSP1 protein expression using the expression plasmid obtained in Example 5, and similar to the case of MDTS6TSP1, it was confirmed that it becomes

pCEP4d and has the influenza virus hemagglutinin secretion signal sequence described in the report (Guan X-M. et al., *J. Biol. Chem.*, 267, 21995 - 21998, 1992), FLAG tag and BamHI recognition sequence in that order downstream of the promoter.

The plasmid pCEP-rAgg was introduced into HEK293-EBNA cell which was subsequently cultured for 3 to 7 days, thereby effecting expression and production of the protein of interest. Purification of the protein of interest from the culture supernatant was carried out by an affinity purification making use of the addition of FLAG tag to the N-terminus. That is, the culture supernatant was applied to M2-agarose (mfd. by Sigma) packed in a column, washed with 20 mM Tris-HCl (pH 7.4)/150 mM NaCl (to be referred to as TBS hereinafter), eluted and fractionated with 0.1 M Gly-HCl (pH 3.0) and immediately neutralized with 1 M Tris-HCl (pH 8.0).

(Example 7-2) Detection of recombinant aggrecan G1G2
degrading activity of MDTS6TSP1 protein

In Example 6, the medium 12 to 16 hours after introduction of the expression plasmid was replaced by a serum-free medium, and the culturing was continued for 32 to 36 hours to recover the culture supernatant. This culture supernatant was mixed with the recombinant aggrecan prepared in the foregoing, and the mixture was allowed to undergo the reaction at 37°C overnight, subjected to SDS-

PAGE, transferred on a PVDF membrane and blocked by the method described in Example 6 and then allowed to react with an anti-Hisx6 polyclonal antibody (sc-803; mfd. by Santa Cruz Biotechnology) and a horseradish peroxidase-labeled goat anti-rabbit IgG polyclonal antibody (mfd. by BML) in that order. After the reaction, the recombinant aggrecan was detected using an ECL western blotting system (mfd. by Amersham Pharmacia). As a result, degraded fragment of the recombinant aggrecan, which was not found in the control in which only the expression plasmid was introduced, was detected (Fig. 2).

(Example 7-3) Analysis by anti-aggrecanase neoepitope antibody

Aggrecanase is a metalloprotease which selectively cleaves aggrecan at the site between Glu³⁷³-Ala³⁷⁴. An antibody capable of recognizing a C-side neoepitope generated by this cleavage was prepared in accordance with a usual method by repeating immunization of mouse with a conjugate of the synthetic peptide represented by SEQ ID NO:32 and KLH, 5 times. A PVDF membrane after transfer and blocking carried out in the same manner as in Example 7-2 was allowed to react with this antibody, allowed to react with a peroxidase-labeled goat anti-mouse IgG polyclonal antibody (mfd. by Tago) and then detected using an ECL western blotting detection system (mfd. by Amersham Pharmacia). As a result, the degraded product of

recombinant aggrecan generated by MDTS6 reacted with the anti-aggrecanase neoepitope antibody, and molecular weight of the detected band is consistent with the molecular weight of the degraded product detected in Example 7-2 (Fig. 3). The same result was obtained by the BC-3 antibody which recognizes aggrecanase neoepitope (Hughes C.E. et al., Biochemical J., 305, 799 - 804, 1995).

(Example 8) Expression induction of MDTS6 mRNA by IL-1

It is known that a mouse cell strain ATDC5 is differentiated into a chondrocyte-like cell by insulin treatment (Atsumi T. et al., Cell Differ. Dev., 30, 109 - 116, 1990). The ATDC5 cells were inoculated in 4 x 10⁵/well portions into an I type collagen-coated 6 well plate (mfd. by Asahi Technoglass) and cultured for 2 days using DMEM/HamF12 (1:1)/5% FCS medium, the medium was changed to DMEM/HamF12 (1:1)/5% FCS medium containing insulin (final concentration 30 ng/ml) and 50 µg/ml of L-ascorbic acid and the culturing was continued for 5 days, and then the resulting cells were treated for 0, 1, 2, 4 or 8 hours by adding IL-1β (final concentration 5 ng/ml). Total RNA was prepared from each of the treated groups using ISOGEN (mfd. by Nippon Gene), and RT-PCR was carried out using 1 µg portion thereof as the template and using BcaBEST™ RNA PCR Kit (mfd. by Takara Shuzo). The reverse transcription reaction was carried out using Oligo dT-

Adaptor Primer as the primer in accordance with the attached instructions, and PCR was carried out using oligoDNA sequences represented by SEQ ID NO:15 and SEQ ID NO:16 as primers, which had been synthesized based on the 3' non-translation region of MDTS6, by the reaction of 94°C for 2 minutes, 40 repetitions of a cycle of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 30 seconds, and subsequent 72°C for 7 minutes. The reaction solution was subjected to electrophoresis with 1% agarose, and densities of the thus generated bands of about 0.3 kbp were compared. As a result, it was found that expression of the MDTS6 mRNA is transiently induced by IL-1 (Fig. 4).

(Example 9) Degradation of natural type aggrecan by MDTS6

(Example 9-1) Expression of various full-length MDTS6 proteins and their recombinant aggrecan G1G2 degrading activity

The expression plasmid constructed using pCEP4dE2-FLAG as the backbone was introduced into HEK293-EBNA cell (mfd. by Invitrogen) using FuGENE™6 Transfection Reagent (mfd. by Boehringer Mannheim) in accordance with the attached instructions. After introduction of the plasmid, the resulting cells were cultured overnight and washed with PBS buffer, and then the medium was changed to a serum-free medium and the culturing was continued for 2 to 3 days. The resulting culture broth was centrifuged at 9,000 rpm

for 10 minutes, and the supernatant was used as the enzyme source of MDTS6. In this case, in addition to the expression plasmids described in Example 4 and Example 5, expression plasmids for three proteins, namely a protein in which the polypeptide represented by SEQ ID NO:33 was added to the C-terminus of the amino acids of from the 1st position to the 447th position of SEQ ID NO:1 (to be referred to as MDTS6Pro hereinafter), a protein in which the polypeptide represented by SEQ ID NO:33 was added to the C-terminus of the amino acids of from the 1st position to the 518th position of SEQ ID NO:1 (to be referred to as MDTS6Dis hereinafter) and a protein in which the polypeptide represented by SEQ ID NO:33 was added to the C-terminus of the amino acids of from the 1st position to the 687th position of SEQ ID NO:1 (to be referred to as MDTS6Cys hereinafter), were designed as expression plasmids for respective full-length MDTS6 proteins. That is, the MDTS6Cys expression plasmid was constructed by amplifying a gene by PCR using the full-length protein expression plasmid constructed in Example 5 as the template and the oligoDNA sequences represented by SEQ ID NO:7 and SEQ ID NO:17 as primers and using PyroBest DNA polymerase, digesting the gene with restriction enzymes XbaI and NotI, and then inserting the resulting fragment into the XbaI-NotI site of pCEP4dE2-FLAG. Also, the MDTS6Pro expression plasmid and the MDTS6Dis expression plasmid were

constructed in the same manner as the plasmid prepared using the MDTS6Cys, illustratively, by digesting respective genes amplified by PCR using PyroBest DNA polymerase with restriction enzymes *Xba*I and *Not*I, and then inserting the resulting fragments into the *Xba*I-*Not*I site of pCEP4dE2-FLAG. Provided that the oligoDNA represented by SEQ ID NO:7 and the oligoDNA represented by SEQ ID NO:34 were used in the case of the MDTS6Pro, and a combination of the oligoDNA represented by SEQ ID NO:7 and the oligoDNA represented by SEQ ID NO:35 was used in the case of the MDTS6dis, respectively.

Regarding protein expression of these respective MDTS6 proteins (MDTS6Cys, MDTS6Pro and MDTS6Dis), they were expressed in the same manner as the expression of MDTS6TSP1 and MDTS6 full-length proteins in an animal cell strain described in (Example 6). When the aggrecanase activity of these respective MDTS6 proteins was examined by the method of Example 7-3, the aggrecanase activity was detected in the culture supernatant in which MDTS6Cys was expressed, but the aggrecanase activity was not detected in the culture supernatants in which MDTS6Pro and MDTS6Dis were expressed. In this connection, molecular weight of the expressed main protein was smaller than the value calculated from the amino acid sequence by a factor of about 23 K and, similar to the case of MDTS6TSP1 described in Example 6, it was mature protein in which the pro region

was cleaved and removed at the furin protease recognition sequence. As a result, it was revealed that the first TSP-1 repeat sequence counting from the N-terminus is essential for exerting the aggrecanase activity of MDTS6.

5 (Example 9-2) Degradation of natural type aggrecan

A 90 μ l portion of the MDTS6 enzyme solution prepared in Example 9-1 was mixed with a solution of 10 μ g natural type aggrecan (mfd. by Seikagaku Kogyo)/10 μ l TBS in a test tube and allowed to undergo the reaction at 37°C overnight.

10 This reaction product was dried up using SpeedVac and then dissolved in 100 μ l of 10 mM Tris-acetate buffer (pH 7.6) containing 0.06 unit of Chondroitinase ABC (mfd. by

Seikagaku Kogyo), 0.024 unit of keratanase I (mfd. by Seikagaku Kogyo), 0.0004 unit of keratanase II (mfd. by

15 Seikagaku Kogyo), 5 μ M of PMSF and 10 mM of EDTA, and the solution was allowed to undergo the reaction at 37°C overnight. A portion of this reaction solution was

subjected to SDS-PAGE and then the product was detected using the mouse anti-aggrecanase neoepitope antibody as

20 shown in Example 7-3. In this case, the peroxidase-labeled goat anti-mouse IgG polyclonal antibody used was a

preparation manufactured by Biosource. The same result was obtained by the BC-3 antibody which recognizes aggrecanase neoepitope (Hughes C.E. et al., Biochemical J., 305, 799 -

25 804, 1995).

As a result, a band of 80 to 90 KDa was detected in the case of MDTS6Cys in addition to a band of about 150 KDa. This degradation pattern is consistent with the pattern of main molecules (all generated by aggrecanase degradation) found in the joint synovial fluids of patients of joint diseases including OA and RA (Sandy J.D. et al., *J. Clin. Invest.*, 89, 1512 - 1516, 1992; Lohmander L.S. et al., *Arthritis Rheum.*, 36, 1214 - 1222, 1993) and also is consistent with the pattern of main molecules having aggrecanase neoepitope which are generated after 12 to 24 hours of treatment with IL-1 and retinoic acid in an explant culture system of human knee joint cartilage (Little C.B. et al., *Biochemical J.*, 344, 61 - 68, 1999) (Fig. 5).

(Example 10) Screening system of substances which modify the aggrecanase activity

(Example 10-1) Preparation of MDTS6Cys and substrate

It was confirmed using the western blotting method shown in Example 9-2 that the recombinant aggrecan G1G2 and the natural type aggrecan are cleaved off at the site between Glu³⁷³-Ala³⁷⁴ (to be referred to as "aggrecanase site" hereinafter") by MDTS6Cys without purification but as the culture supernatant prepared by the method of Example 9-1. Also, the cleavage at the "aggrecanase site" was observed when the culturing in Example 9-1 was continued with the 10% FBS-containing medium without changing to the

serum-free medium. Accordingly, the recombinant aggrecan G1G2 prepared in Example 7-1 was used as the substrate.

(Example 10-2) Screening system

Though the screening can be carried out by the western blotting-aided method shown in Example 7-2 using the recombinant aggrecan or natural type aggrecan as the substrate, the following ELISA system was constructed for screening more larger number of compounds to be tested.

An MDTS6Cys culture supernatant, the recombinant aggrecan G1G2 and a compound to be tested were mixed and allowed to undergo the reaction at 37°C for several hours, the resulting product was adhered to a 96 well plate (Nunc-Immuno™ Plate MaxiSorp™ Surface # 439454; mfd. by Nunc), blocked with 1% BSA/TBS solution and then allowed to react with a mouse anti-aggrecanase neoepitope antibody and an HRP-anti-mouse IgG antibody conjugate (mfd. by Biosource) in that order, and then the detection was carried out using TMB Peroxidase EIA Substrate Kit (mfd. by Bio-Rad) under the conditions described in the attached instructions to calculate the aggrecanase activity inhibiting strength of the compound to be tested using the coloring inhibition as a marker. Also, as a modified method thereof, the recombinant aggrecan was adhered to the 96 well plate (mfd. by Nunc) and blocked with 1% BSA/TBS solution in advance and then an MDTS6Cys culture supernatant and a compound to be tested were added thereto and allowed to undergo the

reaction at 37°C for several hours, the resulting product was allowed to react with a mouse anti-aggrecanase neoepitope antibody and an HRP-anti-mouse IgG antibody conjugate (mfd. by Biosource) in that order, and then the
5 detection was carried out using TMB Peroxidase EIA Substrate Kit (mfd. by Bio-Rad) to calculate the aggrecanase activity inhibiting strength of the compound to be tested using the coloring inhibition as a marker. The criterion to screen a substance which inhibits the
10 aggrecanase activity is preferably 10 μM or less, more preferably 1.0 μM or less, as inhibition activity strength (IC_{50}).

By this screening system, it was able to select the aforementioned compound A, compound B, compound C and
15 compound D. The aggrecanase activity inhibition strength (IC_{50}) was 0.6 μM for the compound A, 1.0 μM for the compound B, 2.9 μM for the compound C and 2.7 μM for the compound D.

In this connection, the compound A, compound B,
20 compound C and compound D were synthesized in the same manner as the production method described in PCT publication number WO 90/05719. The mass spectrum of respective compounds is as follows. The compound A is $\text{MS} = 426 (\text{MH}^+)$, the compound B is $\text{MS} = 396 (\text{MH}^+)$, the compound C
25 is $\text{MS} = 502 (\text{MH}^+)$ and the compound D is $\text{MS} = 440 (\text{MH}^+)$.

(Example 11)

(Example 11-1) Preparation of rabbit knee joint
cartilage primary culture cells

After killing a rabbit (Japanese white species, male,
5 1.0 to 1.5 kg) under excess anesthesia, a knee joint was
excised and the cartilage layer on the joint surface was
removed and finely cut using a surgical knife. The cut
pieces were treated with trypsin-EDTA (0.25%-1 mM; mfd. by
GIBCO-BRL) at 37°C for 1 hour and then centrifuged at 1,500
10 rpm for 5 minutes, and the resulting precipitate was washed
with DMEM. This was treated with collagenase A (0.15%;
Boehringer-Mannheim)/DMEM at 37°C for 3 to 4 hours, and
then a nylon mesh filter (100 µm, mfd. by Falcon)-passed
fraction was centrifuged at 1,500 rpm for 5 minutes to
15 effect precipitation of cartilage cells. The cells were
thoroughly washed with DMEM/10% FBS medium, suspended in
DMEM/10% FBS medium to a density of 2×10^5 cells/ml and
then inoculated in 200 µl/well portions into an I type
collagen-coated 96 well plate (mfd. by Asahi Technoglass).
20 Three days thereafter, the medium was changed to 200 µl of
DMEM/10% FBS medium containing 50 µg/ml of ascorbic acid
(ascorbic acid medium hereinafter), and the culturing was
continued for 3 days. When an I type collagen-coated 6
well plate (Asahi Technoglass) was used, the cell
25 suspension was inoculated in 6 ml/well portions and

cultured by carrying out the same medium exchange. These cells were used in the following test.

(Example 11-2) Proteoglycan degradation of rabbit knee joint cartilage primary culture cells

5 The rabbit knee joint cartilage primary culture cells of 96 well plate described in Example 11-1 were cultured for 2 days using 200 μ l of the ascorbic acid medium supplemented with 10 μ Ci/ml in final concentration of $\text{Na}_2^{35}\text{SO}_4$ and labeled therewith, washed 3 times with 200 μ l
10 of the ascorbic acid medium and then cultured for 1 day using 200 μ l of the ascorbic acid medium. After stimulation with IL-1 β or all-trans retinoic acid and subsequent 0, 24, and 48 hours of culturing, the culture supernatants were recovered in 20 μ l portions, and the
15 radioactivity was measured using Top Count (mfd. by Packard). As a result, increase in the radioactivity, namely release of proteoglycan, was observed by 0.01 to 10 ng/ml of IL-1 β stimulation, and increase in the concentration-dependent and strong radioactivity, namely
20 release of proteoglycan, was observed by 0.1 to 10 μ M of all-trans retinoic acid stimulation (Fig. 6).

(Example 11-3) Induction of MDTS6 mRNA expression

After 3 days of culturing of the rabbit knee joint cartilage primary culture cells of 6 well plate described
25 in Example 11-1 by changing the medium to ascorbic acid medium, 10 ng/ml of IL-1 β or 10 μ M of all-trans retinoic

acid was added thereto, and total RNA samples 2 and 6 hours thereafter were prepared using ISOGEN (mfd. by Nippon Gene) in accordance with the attached instructions. Each of the samples was treated with DNase I (mfd. by Nippon Gene),
5 subjected to phenol/chloroform treatment and then recovered by ethanol precipitation, and the thus purified total RNA was dissolved in DEPC-treated sterile water. Using random hexamers as primers, 1 µg of this total RNA was subjected to reverse transcription reaction and RNase H treatment
10 using Thermoscript™ RT-PCR System (mfd. by GIBCO-BRL, catalog number 11146-016) in accordance with the attached instructions, and the product was diluted 10 times with sterile water and used as a cDNA sample. Using 5 µl of each of the thus obtained cDNA samples as the template and
15 the oligoDNA sequences represented by SEQ ID NO:18 and SEQ ID NO:19 as primers, PCR was carried out under a condition of 94°C for 2 minutes, 45 repetitions of a cycle of 94°C for 30 seconds, 65°C for 30 seconds and 72°C for 30 seconds, and subsequent 72°C for 10 minutes. The reaction
20 products were subjected to 2% agarose electrophoresis, and densities of the generated DNA fragments were compared. As a result, expression of the MDTS6 mRNA was induced by IL-1β and all-trans retinoic acid, and the expression strength correlated with the degree of proteoglycan degradation
25 described in Example 11-2 (Fig. 7).

(Example 12) Inhibition of proteoglycan degradation
in rabbit knee joint cartilage primary culture cells by
substances which inhibit the aggrecanase activity

Each of the compounds A, B, C and D selected by the
5 screening system of Example 10-2 was added to the
proteoglycan degradation system of rabbit knee joint
cartilage primary culture cells just before the stimulation
with 10 μ M of all-trans retinoic acid, and their
proteoglycan degradation inhibitory activities were
10 examined. As a result, the compounds A and B showed the
inhibition of proteoglycan degradation in a concentration-
dependent manner (Fig. 8). The proteoglycan degradation
inhibition action (IC_{50}) of the compounds C and D was 6.3
 μ M for the compound C and 4.1 μ M for the compound D. On
15 the other hand, the proteoglycan degradation inhibition
action was not observed by compounds which have the same
hydroxamic acid backbone but show a weak aggrecanase
activity inhibition, even at a concentration of 100 μ M.

(Example 13) Analysis of MDTS6 promoter region DNA
20 sequence

A DNA fragment corresponding to the promoter region
of MDTS6 was amplified using PCR from GenomeWalker DNA Sca
I Libraries (Genome WalkerTM Kits, CLONTECH catalog number
K1803-1). OligoDNA sequences of the adapter primers AP-1
25 (SEQ ID NO:20) and AP-2 (SEQ ID NO:21) attached to the kit
were used as forward primers, and the oligoDNA sequences of

SEQ ID NO:22 and SEQ ID NO:23 as reverse primers. The illustrative method was as described in the instructions attached to the kit, but TAKARA LA Taq (TAKARA LA TaqTM, catalog number RR002A) was used in the PCR. The first PCR was carried out using the oligoDNA sequences of SEQ ID NO:20 and SEQ ID NO:22 as primers under a condition of 7 repetitions of a cycle of 98°C for 5 seconds and 72°C for 3 minutes, 32 repetitions of a cycle of 98°C for 5 seconds and 67°C for 3 minutes, and 67°C for 4 minutes. The second PCR was carried out under the same conditions using 5 µl of a solution prepared by diluting the reaction solution of the first reaction 50 times with TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) as the template, and the oligoDNA sequences of SEQ ID NO:21 and SEQ ID NO:23 as primers. When the thus amplified DNA fragment of about 3.7 kbp was directly subjected to sequence analysis by dideoxy terminator method using ABI377 DNA Sequencer (Applied Biosystems Inc.), DNA sequences of about 2.2 kbp, 0.36 kbp and 0.8 kbp divided by two un-decipherable gaps were found. Next, in order to decipher sequences of these two gap moieties which were unable to decipher by the direct analysis of the PCR-amplified DNA fragment, this DNA fragment was subcloned and the DNA nucleotide sequence was determined. As a result, sequences of the gap moieties were different in the determined 8 clones (SEQ ID NOs:24, 25, 26, 27, 28, 29, 30 and 31), so that the presence of

gene polymorphism was suggested. In this connection,
pZErOTM-2 vector (Zero Background/Kan Cloning Kit, mfd. by
Invitrogen, catalog number K2600-01) was used as the
cloning vector, and the subcloning was carried out in
5 accordance with the attached instructions.

A plasmid prepared by inserting the above DNA
fragment into the KpnI-XhoI site of a reporter plasmid pGV-
B2 (mfd. by Toyo Ink) was introduced into HEK293 cell using
FuGene-6, and the luciferase activity after 28 or 48 hours
10 of culturing under usual culturing conditions was measured
using PicaGene coloring kit (mfd. by Toyo Ink, catalog
number PGK-L100). In this case, the measured value was
normalized by the activity value of β -gal expressed by a
simultaneously introduced β -gal expression plasmid pCH110
15 (Amersham Pharmacia Biotech, catalog number 27-4508-01).
The β -gal activity was measured using Galacto-Light Plus
Kit (mfd. by TROPIX, catalog number BL300P). As a result,
distinct increase in the luciferase activity which cannot
be found in the original plasmid pGV-B2 was observed. This
20 result indicates that the promoter activity is present in
the above DNA fragment.

(Example 14) Expression of MDTS6 in joint tissue of
osteoarthritis patient

Total RNA was prepared from an affected part of a
25 knee joint cartilage of an osteoarthritis patient (Adams
M.E. et al., *Anal. Biochem.*, 202, 89 - 95, 1992), and the

presence of MDTS6 mRNA was confirmed by carrying out RT-PCR using this as the template in accordance with Example 11-3. Also, the presence of MDTS6 protein in synovial membrane and macrophage was confirmed by carrying out immunological tissue staining using a mouse anti-human MDTS6-specific polyclonal antibody.

In this connection, the mouse anti-human MDTS6-specific polyclonal antibody was prepared in the following manner. Firstly, the MDTS6TSP1 protein prepared in Example 6 was conjugated with KLH, and mice were immunized with this 4 to 5 times to obtain an antiserum sample. Next, IgG was prepared from this antiserum using Protein G Sepharose 4 Fast Flow (mfd. by Amersham Pharmacia Biotech) in accordance with the attached instructions. Next, a column in which the human MDTS6TSP1 protein was fixed to CNBr-activated Sepharose 4 Fast Flow (mfd. by Amersham Pharmacia Biotech) was prepared in accordance with the attached instructions. Thereafter, a fraction was prepared which binds to this column but does not bind to a column immobilized with human ADAMTS4TSP1 protein (aggrecanase-1; Tortorella M.D. et al., *Science*, 284, 1664 - 1666, 1999), METH-1TSP1 protein (Vazquez F. et al., *J. Biol. Chem.*, 274, 23349 - 57, 1999) or METH-2TSP1 protein (Vazquez F. et al., *J. Biol. Chem.*, 274, 23349 - 57, 1999).

Industrial Applicability

The "joint disease aggrecanase" obtained by the invention is characterized in that it can be used for the screening of a substance which significantly inhibits the aggrecanase (a compound, a peptide, an antibody or an antibody fragment), because it has an aggrecanase activity. Regarding the medicinal use of the substance which significantly inhibits the "joint disease aggrecanase", it is suggested that it is effective in preventing and treating diseases which are caused by abnormalities (e.g., acceleration, reduction, degeneration and the like) of the aggrecanase activity or in which the abnormalities are expressed to cause complications, particularly joint diseases as diseases which show acceleration of proteoglycan degradation, most particularly osteoarthritis.

Also, the promoter gene of the "joint disease aggrecanase" of the invention is characterized in that it can be used for the screening of a substance which inhibits promoter activity of the gene (a compound, a peptide, an antibody or an antibody fragment). As the use of the substance which inhibits the promoter activity, it is suggested that it is effective in preventing and treating diseases caused by inhibition of the promoter activity, particularly joint diseases as diseases which show acceleration of proteoglycan degradation, most particularly osteoarthritis. In addition, since two or more mutants are

present in the promoter gene, they can be used for their correlation analysis with these diseases.

Claims in the Amendment

[Received by the International Bureau on April 19, 2001
(19. 04. 01): claims 1 to 4 and 7 to 11 in the first
application were amended; other claims were unchanged. (2
pages)]

1. (after amendment) A metalloprotease having an
aggrecanase activity, which comprises an amino acid
sequence of from the 213th position to the 583rd position
of an amino acid sequence represented by SEQ ID NO:1 or
which consists of an amino acid sequence of from the 213th
position to the 583rd position of the amino acid sequence
represented by SEQ ID NO:1 wherein from 1 to 10 amino acid
residues are substituted, deleted and/or inserted.

2. (after amendment) A metalloprotease having an
aggrecanase activity, which comprises an amino acid
sequence of from the 1st position to the 583rd position of
an amino acid sequence represented by SEQ ID NO:1 or which
consists of an amino acid sequence of from the 1st position
to the 583rd position of the amino acid sequence
represented by SEQ ID NO:1 wherein from 1 to 10 amino acid
residues are substituted, deleted and/or inserted.

3. (after amendment) A metalloprotease having an
aggrecanase activity, which consists of an amino acid
sequence represented by SEQ ID NO:1, an amino acid sequence
of from the 1st position to the 687th position of an amino
acid sequence represented by SEQ ID NO:1, an amino acid

sequence of from the 1st position to the 583rd position of
the amino acid sequence represented by SEQ ID NO:1, an
amino acid sequence of from the 213th position to the 950th
position of the amino acid sequence represented by SEQ ID
5 NO:1, an amino acid sequence of from the 213th position to
the 687th position of the amino acid sequence represented
by SEQ ID NO:1 or an amino acid sequence of from the 213th
position to the 583rd position of the amino acid sequence
represented by SEQ ID NO:1, or any one of these sequences
10 wherein from 1 to 10 amino acid residues are substituted,
deleted and/or inserted.

4. (after amendment) A gene which encodes an amino
acid sequence of the metalloprotease having an aggrecanase
activity described in any one of claims 1 to 3.

15 5. A vector which comprises the gene described in
claim 4.

6. A host cell which comprises the vector described
in claim 5.

7. (after amendment) A method for producing the
20 metalloprotease having an aggrecanase activity described in
any one of claims 1 to 3, which comprises using the host
cell described in claim 6.

8. (after amendment) An antibody against the
metalloprotease having an aggrecanase activity described in
25 any one of claims 1 to 3.

9. (after amendment) A method for screening a substance capable of inhibiting an aggrecanase activity of a metalloprotease, which comprises allowing the metalloprotease having an aggrecanase activity described in
5 any one of claims 1 to 3 to contact with a compound to be tested.


10. (after amendment) A pharmaceutical composition for inhibiting degradation of proteoglycans, which comprises a substance capable of inhibiting the
10 metalloprotease having an aggrecanase activity described in any one of claims 1 to 3, as an active ingredient.

11. (after amendment) A gene represented by SEQ ID NO:24, 25, 26, 27, 28, 29, 30 or 31, or a gene represented by SEQ ID NO:24, 25, 26, 27, 28, 29, 30 or 31 wherein from
15 1 to 10 amino acid residues are substituted, deleted and/or inserted, which has a joint disease aggrecanase promoter activity.

10/009332


1/8

FIG. 1




2/8

FIG. 2



3/8


FIG. 3



4/8

FIG. 4

IL-1 Treatment (Time) 0 1 2 4 8



5/8

FIG. 5

	EDTA	-	+	-	+
M.W. Marker					
MDTS6TSP 1					
MDTS6Cys					

KDa


211

122

80


51

40



6/8

FIG. 6



7/8

FIG. 7


1 2 3 4 5



- 1: No Treatment
- 2: IL-1 β 2 hours Treatment
- 3: R.A. 2 hours Treatment
- 4: IL-1 β 6 hours Treatment
- 5: R.A. 6 hours Treatment

8/8

FIG. 8



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL METALLOPROTEASE HAVING AGGREGANASE ACTIVITY

the specification of which is attached hereto unless the following box is checked:

☒ was filed on November 10, 2000 as ~~United States Application Number~~ PCT International Application Number PCT/JP00/07917 and was amended on April 10, 2001 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information of which is material to the patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

<u>P. Hei. 11-321740</u> (Number)	<u>Japan</u> (Country)	<u>11/November/1999</u> (Day/Month/Year Filed)	<input type="checkbox"/>
<u>P. 2000-144020</u> (Number)	<u>Japan</u> (Country)	<u>16/May/2000</u> (Day/Month/Year Filed)	<input type="checkbox"/>
<u> </u> (Number)	<u> </u> (Country)	<u> </u> (Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefits under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

I hereby claim the benefits under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Application Number)

(Filing Date)

(Status - patented, pending, abandoned)

(Application Number)

(Filing Date)

(Status - patented, pending, abandoned)

I hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Scott M. Daniels, Reg. No. 32,562; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765 and Robert M. Masters, Reg. No. 35,603; my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date November 29, 2001 First Inventor Noboru YAMAJI
First Name Last Name

Residence Ibaraki Signature Noboru Yamaji
Japan Post Office Address c/o Yamanouchi Pharmaceutical Co., Ltd.
21, Miyukigaoka, Tsukuba-shi,
Citizenship Japan Ibaraki 305-8585 Japan

Date November 29, 2001 Second Inventor Kouichi NISHIMURA
First Name Last Name

Residence Ibaraki Signature Kouichi Nishimura
Japan Post Office Address c/o Yamanouchi Pharmaceutical Co., Ltd.
21, Miyukigaoka, Tsukuba-shi,
Citizenship Japan Ibaraki 305-8585 Japan

Date November 29, 2001 3rd Third Inventor Kunitake ABE
First Name Last Name
Residence Ibaraki, JPY Signature Kunitake Abe
Japan Post Office Address c/o Yamanouchi Pharmaceutical Co., Ltd.
Citizenship Japan 21, Miyukigaoka, Tsukuba-shi,
Ibaraki 305-8585 Japan

Date November 29, 2001 4th Fourth Inventor Osamu OHARA
First Name Last Name
Residence Chiba, JPY Signature Osamu Ohara
Japan Post Office Address 20-25, Jozai 2-chome, Kisarazu-shi,
Citizenship Japan Chiba 292-0801 Japan

Date November 29, 2001 5th Fifth Inventor Takahiro NAGASE
First Name Last Name
Residence Chiba, JPY Signature Takahiro Nagase
Japan Post Office Address 6-5, Kiyomidai-minami 2-chome, Kisarazu-shi,
Citizenship Japan Chiba 292-0042 Japan

Date November 29, 2001 6th Sixth Inventor Nobuo NOMURA
First Name Last Name
Residence Chiba, JPY Signature Nobuo Nomura
Japan Post Office Address 2-11, Hachimandai 5-chome, Kisarazu-shi,
Citizenship Japan Chiba 292-0814 Japan

Date _____ Seventh Inventor _____
First Name Last Name
Residence _____ Signature _____
Post Office Address _____
Citizenship _____

Date _____ Eighth Inventor _____
First Name Last Name
Residence _____ Signature _____
Post Office Address _____
Citizenship _____

(Supply similar information for ninth and subsequent joint inventors.)

10/009332

SEQUENCE LISTING

<110> Yamanouchi Pharmaceutical Co., Ltd.
Kazusa DNA Research Institute

<120> NOVEL METALLOPROTEASE HAVING AGGREGANASE ACTIVITY

<130> Q67541

<150> JPA Hei 11-321740

<151> 1999-11-11

<150> JPA 2000-144020

<151> 2000-05-16

<160> 35

<170> PatentIn version 3.1

<210> 1

<211> 950

<212> PRT

<213> Homo sapiens

<400> 1

Met Leu Leu Leu Gly Ile Leu Thr Leu Ala Phe Ala Gly Arg Thr Ala
1 5 10 15

Gly Gly Phe Glu Pro Glu Arg Glu Val Val Val Pro Ile Arg Leu Asp
20 25 30

Pro Asp Ile Asn Gly Arg Arg Tyr Tyr Trp Arg Gly Pro Glu Asp Ser
35 40 45

Gly Asp Gln Gly Leu Ile Phe Gln Ile Thr Ala Phe Gln Glu Asp Phe
50 55 60

Tyr Leu His Leu Thr Pro Asp Ala Gln Phe Leu Ala Pro Ala Phe Ser
65 70 75 80

Thr Glu His Leu Gly Val Pro Leu Gln Gly Leu Thr Gly Gly Ser Ser
85 90 95

Asp Leu Arg Arg Cys Phe Tyr Ser Gly Asp Val Asn Ala Glu Pro Asp
100 105 110

Ser Phe Ala Ala Val Ser Leu Cys Gly Gly Leu Arg Gly Ala Phe Gly
115 120 125

Tyr Arg Gly Ala Glu Tyr Val Ile Ser Pro Leu Pro Asn Ala Ser Ala
130 135 140

Pro Ala Ala Gln Arg Asn Ser Gln Gly Ala His Leu Leu Gln Arg Arg
145 150 155 160

Gly Val Pro Gly Gly Pro Ser Gly Asp Pro Thr Ser Arg Cys Gly Val
165 170 175

Ala Ser Gly Trp Asn Pro Ala Ile Leu Arg Ala Leu Asp Pro Tyr Lys
180 185 190

Pro Arg Arg Ala Gly Phe Gly Glu Ser Arg Ser Arg Arg Arg Ser Gly
195 200 205

Arg Ala Lys Arg Phe Val Ser Ile Pro Arg Tyr Val Glu Thr Leu Val
210 215 220

Val Ala Asp Glu Ser Met Val Lys Phe His Gly Ala Asp Leu Glu His
225 230 235 240

Tyr Leu Leu Thr Leu Leu Ala Thr Ala Ala Arg Leu Tyr Arg His Pro
245 250 255

Ser Ile Leu Asn Pro Ile Asn Ile Val Val Val Lys Val Leu Leu Leu
260 265 270

Arg Asp Arg Asp Ser Gly Pro Lys Val Thr Gly Asn Ala Ala Leu Thr
275 280 285

Leu Arg Asn Phe Cys Ala Trp Gln Lys Lys Leu Asn Lys Val Ser Asp
290 295 300

Lys His Pro Glu Tyr Trp Asp Thr Ala Ile Leu Phe Thr Arg Gln Asp
305 310 315 320

Leu Cys Gly Ala Thr Thr Cys Asp Thr Leu Gly Met Ala Asp Val Gly
325 330 335

Thr Met Cys Asp Pro Lys Arg Ser Cys Ser Val Ile Glu Asp Asp Gly
340 345 350

Leu Pro Ser Ala Phe Thr Thr Ala His Glu Leu Gly His Val Phe Asn
355 360 365

Met Pro His Asp Asn Val Lys Val Cys Glu Glu Val Phe Gly Lys Leu
370 375 380

Arg Ala Asn His Met Met Ser Pro Thr Leu Ile Gln Ile Asp Arg Ala
385 390 395 400

Asn Pro Trp Ser Ala Cys Ser Ala Ala Ile Ile Thr Asp Phe Leu Asp
405 410 415

Ser Gly His Gly Asp Cys Leu Leu Asp Gln Pro Ser Lys Pro Ile Ser
420 425 430

Leu Pro Glu Asp Leu Pro Gly Ala Ser Tyr Thr Leu Ser Gln Gln Cys
435 440 445

Glu Leu Ala Phe Gly Val Gly Ser Lys Pro Cys Pro Tyr Met Gln Tyr
450 455 460

Cys Thr Lys Leu Trp Cys Thr Gly Lys Ala Lys Gly Gln Met Val Cys
465 470 475 480

Gln Thr Arg His Phe Pro Trp Ala Asp Gly Thr Ser Cys Gly Glu Gly
485 490 495

Lys Leu Cys Leu Lys Gly Ala Cys Val Glu Arg His Asn Leu Asn Lys
500 505 510

His Arg Val Asp Gly Ser Trp Ala Lys Trp Asp Pro Tyr Gly Pro Cys
515 520 525

Ser Arg Thr Cys Gly Gly Gly Val Gln Leu Ala Arg Arg Gln Cys Thr
530 535 540

Asn Pro Thr Pro Ala Asn Gly Gly Lys Tyr Cys Glu Gly Val Arg Val
545 550 555 560

Lys Tyr Arg Ser Cys Asn Leu Glu Pro Cys Pro Ser Ser Ala Ser Gly
565 570 575

Lys Ser Phe Arg Glu Glu Gln Cys Glu Ala Phe Asn Gly Tyr Asn His
580 585 590

Ser Thr Asn Arg Leu Thr Leu Ala Val Ala Trp Val Pro Lys Tyr Ser
595 600 605

Gly Val Ser Pro Arg Asp Lys Cys Lys Leu Ile Cys Arg Ala Asn Gly
610 615 620

Asp Cys Arg Gly Ser Ala Gly Gln Arg Thr Val Pro Ala Cys Asp Ala
865 870 875 880

Ala His Arg Pro Val Glu Thr Gln Ala Cys Gly Glu Pro Cys Pro Thr
885 890 895

Trp Glu Leu Ser Ala Trp Ser Pro Cys Ser Lys Ser Cys Gly Arg Gly
900 905 910

Phe Gln Arg Arg Ser Leu Lys Cys Val Gly His Gly Gly Arg Leu Leu
915 920 925

Ala Arg Asp Gln Cys Asn Leu His Arg Lys Pro Gln Glu Leu Asp Phe
930 935 940

Cys Val Leu Arg Pro Cys
945 950

<210> 2
<211> 2853
<212> DNA
<213> Homo sapiens

<400> 2
atgcttttgc tgggcatcct aaccctggct ttcgccgggc gaaccgctgg aggcttttgag 60
ccagagcggg aggtagtcgt tcccatccga ctggaccgag acattaacgg ccgccgctac 120
tactggcggg gtcccgagga ctccggggat cagggactca tttttcagat cacagcattt 180
caggaggact tttaacctaca cctgacgccg gatgctcagt tcttggtcc cgccttctcc 240
actgagcatc tgggcgtccc cctccagggg ctcaccgggg gctcttcaga cctgcgacgc 300
tgcttctatt ctggggacgt gaacgccgag ccggactcgt tcgctgctgt gagcctgtgc 360
ggggggctcc gcggagcctt tggctaccga ggcgccgagt atgtcattag cccgctgccc 420
aatgctagcg cgcgggcggc gcagcgcaac agccagggcg cacaccttct ccagcgccgg 480
ggtgttccgg gcgggccttc cggagacccc acctctcgct gcgggggtggc ctcgggctgg 540
aaccccgcca tcctacgggc cctggaccct tacaagccgc ggcggggcggg cttcggggag 600
agtcgtagcc ggcgcaggtc tgggcgcgcc aagcgtttcg tgtctatccc gcggtacgtg 660
gagacgctgg tggtcgcgga cgagtcaatg gtcaagttcc acggcgcgga cctggaacat 720
tatctgctga cgctgctggc aacggcggcg cgactctacc gccatcccag catcctcaac 780
cccatcaaca tcgttgtggg caaggtgctg cttcttagag atcgtgactc cgggcccgaag 840

gtcaccggca atgcgggcct gacgctgcgc aacttctgtg cctggcagaa gaagctgaac 900
aaagtgagtg acaagcacc cagactactgg gacactgcca tcctcttcac caggcaggac 960
ctgtgtggag ccaccacctg tgacaccctg ggcatggctg atgtgggtac catgtgtgac 1020
cccaagagaa gctgctctgt cattgaggac gatgggcttc catcagcctt caccactgcc 1080
cacgagctgg gccacgtgtt caacatgccc catgacaatg tgaaagtctg tgaggaggtg 1140
tttgggaagc tccgagccaa ccacatgatg tccccgacc tcatccagat cgaccgtgcc 1200
aaccctggt cagcctgcag tgctgccatc atcaccgact tcctggacag cgggcacggt 1260
gactgcctcc tggaccaacc cagcaagccc atctccctgc ccgaggatct gccgggcgcc 1320
agctacaccc tgagccagca gtgcgagctg gcttttggcg tgggctccaa gccctgtcct 1380
tacatgcagt actgcaccaa gctgtggtgc accgggaagg ccaagggaca gatggtgtgc 1440
cagaccgcc acttccctg ggccgatggc accagctgtg gcgagggcaa gctctgcctc 1500
aaaggggcct gcgtggagag acacaacctc aacaagcaca ggggtggatgg ttctgggcc 1560
aaatgggatc cctatggccc ctgctcgcgc acatgtggtg ggggcgtgca gctggccagg 1620
aggcagtga ccaacccac ccctgccaac gggggcaagt actgcgagg agtgagggtg 1680
aaataccgat cctgcaacct ggagccctgc ccagctcag cctccgaaa gagcttccgg 1740
gaggagcagt gtgaggcttt caacggctac aaccacagca ccaaccggct cactctcgcc 1800
gtggcatggg tgcccaagta ctccggcgtg tctccccggg acaagtgcaa gctcatctgc 1860
cgagccaatg gcaactggta cttctatgtg ctggcaccca aggtggtgga cggcacgctg 1920
tgctctcctg actccacctc cgtctgtgtc caaggcaagt gcatcaaggc tggctgtgat 1980
gggaacctgg gctccaagaa gagattcgac aagtgtggg tgtgtgggg agacaataag 2040
agctgcaaga aggtgactgg actcttcacc aagcccatgc atggctacaa tttcgtggtg 2100
gccatccccg caggcgctc aagcatcgac atccgccagc gcggttacia agggctgatc 2160
gggatgaca actacctggc tctgaagaac agccaaggca agtacctgct caacgggcat 2220
ttcgtggtgt cggcggtgga gcgggacctg gtggtgaagg gcagtctgct gcggtacagc 2280
ggcacgggca cagcggtgga gagcctgcag gcttcccgcc ccatcctgga gccgctgacc 2340
gtggagggtc tctccgtggg gaagatgaca ccgccccggg tccgctactc cttctatctg 2400
cccaaagagc ctcgggagga caagtccctc catcccaagg acccccggg accctctgtc 2460
ttgcacaaca gcgtccctcag cctctccaac cagggtggagc agccggacga caggccccct 2520
gcacgctggg tggctggcag ctgggggccc tgctccgcga gctgcggcag tggcctgcag 2580
aagcgggcgg tggactgccg gggctccgcc gggcagcgca cggtcctgc ctgtgatgca 2640

gccccatcggc ccgtggagac acaagcctgc ggggagccct gccccacctg ggagctcagc 2700
gcctgggtcac cctgctccaa gagctgcggc cggggatttc agaggcgctc actcaagtgt 2760
gtggggccacg gaggccggct gctggcccg gaccagtgc acttgaccg caagccccag 2820
gagctggact tctgcgtcct gaggccgtgc tga 2853

<210> 3
<211> 50
<212> DNA
<213> Homo sapiens

<400> 3
ctagcgcggc cgcaggatcc gactacaagg acgacgatga caaatgataa 50

<210> 4
<211> 50
<212> DNA
<213> Homo sapiens

<400> 4
gatcttatca tttgtcatcg tcgtccttgt agtcggatcc tgcggccgcg 50

<210> 5
<211> 34
<212> DNA
<213> Homo sapiens

<400> 5
ggactagtct agaagctggg taccagctgc tagc 34

<210> 6
<211> 29
<212> DNA
<213> Homo sapiens

<400> 6
ggactagtgt cgaccggtca tggctgcgc 29

<210> 7
<211> 42
<212> DNA
<213> Homo sapiens

<400> 7
gtgtctagag ccatgctttt gctgggcac ctaaccctgg ct 42

<210> 8
<211> 41
<212> DNA
<213> Homo sapiens

<400> 8

agagcggccg cctgctcctc ccggaagctc tttccggagg c

41

<210> 9
<211> 27
<212> DNA
<213> Homo sapiens

<400> 9
aagcacaggg tggatggttc ctgggcc

27

<210> 10
<211> 37
<212> DNA
<213> Homo sapiens

<400> 10
gcgcggccgc gcacggcctc aggacgcaga agtccag

37

<210> 11
<211> 37
<212> DNA
<213> Homo sapiens

<400> 11
taggatcctt gtagaaactt cagaccatga caactcg

37

<210> 12
<211> 59
<212> DNA
<213> Homo sapiens

<400> 12
atggatcctc aatggtgatg gtgatgatga ccgaagcaga aggcattggtg ccgggacag

59

<210> 13
<211> 97
<212> DNA
<213> Homo sapiens

<400> 13
agcttgccac catgaagacg atcatcgccc tgagctacat cttctgcctg gtattcgccg

60

actacaagga cgatgatgac aaggggatcc actagtc

97

<210> 14
<211> 97
<212> DNA
<213> Homo sapiens

<400> 14
tcgagactag tggatcccct tgatcatc gtccttgtag tcggcgaata ccaggcagaa

60

gatgtagctc agggcgatga tcgtttcat ggtggca

97

<210> 15
<211> 30
<212> DNA
<213> Homo sapiens

<400> 15
acctcagcag ccagctccct tgtatacaca

30

<210> 16
<211> 30
<212> DNA
<213> Homo sapiens

<400> 16
cttgaggggg atggaccaat acagctttgg

30

<210> 17
<211> 38
<212> DNA
<213> Homo sapiens

<400> 17
agagcgggccg ctccagtcac cttcttgag ctcttatt

38

<210> 18
<211> 27
<212> DNA
<213> Homo sapiens

<400> 18
gcggacgagt ccatgggtcaa gttccac

27

<210> 19
<211> 27
<212> DNA
<213> Homo sapiens

<400> 19
ttctgccagg cgcagaagtt gcgcagc

27

<210> 20
<211> 22
<212> DNA
<213> Homo sapiens

<400> 20
gtaatacgac tcactatagg gc

22

<210> 21
<211> 19
<212> DNA
<213> Homo sapiens

<400> 21
actatagggc acgcgtggt 19

<210> 22
<211> 30
<212> DNA
<213> Homo sapiens

<400> 22
actgagcatc cggcgtcagg ttaggtaaa 30

<210> 23
<211> 30
<212> DNA
<213> Homo sapiens

<400> 23
agtcctcctg aaatgctgtg atctgaaaaa 30

<210> 24
<211> 3473
<212> DNA
<213> Homo sapiens

<220>
<221> promoter
<222> (1)..(3473)
<223>

<400> 24
ttgcacagct aagatctggt ggagggcatgc acacagggcc ctctgaccat gggctctaaa 60
tcactgtact atgttccctt ccataggcct caatcagtca tgtaatattt gacctggtcg 120
ttatcttagg tattatctag accacagatt ttggatgcag ttctctggct gaagacctct 180
gagctaggat aaccccttct cttttgacag acgagtcaga gaatcagatc agtgatagaa 240
gtggagtgcc aatcctgagt atcacctcta ctcaagtgc caacatatcc ctgatacctc 300
aattccctgg caaaagtgat tggatggaac cacaggcttc caagagggga cagtcaagca 360
ttaaatacga gaatgcacat ataactcttg gtgcaatgtt tagcacatac taagcctgca 420
atacatgcta atccctttga gcaaatecac atggccagtt tctgtgctca ggggtgagaa 480
tagctgggct gtgattgggg cagggggagc actaagtggg agggacttcc tgtctcaggt 540
ccctgccatc ttgactgaca tgctgcagcc cttgccaaaa cccatgggtc agaataaaag 600
taaagtgccg ttgaaaacct tgcaatccac ctttaaaact gccgggtgta gtaaaacaat 660
tgcttgcccc aaataaatga cttatcattg ctggttggtg tctgcgtttc tctttaatta 720
taggccctct ttgaacgctc aaacacacag ggcctttgta agcttgaact ccctgtctca 780

ccttgccatc	ttgactgaca	tgctgcagcc	cttgccaaaa	cccatggggtc	agaatgaaag	600
taaagtgccg	ttgaaaacct	tgcaatccac	ctttaaaact	gccgggtgta	gtaaaacaat	660
tgcttgcccc	aaataaatga	cttatcattg	ctgttggttg	tctgcgtttc	tctttaatta	720
taggccctct	ttgaacgctc	aaacacacag	ggcctttgta	agcttgaact	ccctgtctca	780
cacacagtcc	tcccatacc	atacactctc	tttcatttgc	agagtataaa	cacccatctc	840
tcactcattc	acataatgaa	tttcagctcc	ttgtgtccca	atcaaggaga	ggcctcactg	900
gaattatggg	catctgagcc	atcttcatgt	tccaaggccc	cagggggcgc	ttccaagagt	960
ggatccttta	tggggagaag	ataatgggca	aaaagtgctc	ttcactgatg	gaccagtccc	1020
agccttttct	ctccttggac	aatagagttc	ttcccttgaa	cagccacttc	cctaaaaaaaa	1080
attccaaaat	tctcccat	catccccttt	atgcttaaaa	tcatcacaca	ctcccttctt	1140
tgtcctcccc	tcttgcaaac	tcaactcaga	gccctttggc	tccagaaaga	ttttctaggt	1200
atcaggagag	agtagcaaag	cctccctcct	ctccttgcc	ttctcccttg	tcagagaaag	1260
aagttgattc	tgcgagagg	taagaaggat	cttgaggct	agagcctgaa	aaactccttg	1320
ggctgttctc	caaactagat	gggaacataa	ggtgcgattg	catcttctcc	agctgatact	1380
cactcggcct	cctatgccag	tccccagtc	agggtttggt	caagggtcaa	atgagataat	1440
ttcatggagg	aagcctggcc	cgatttttct	actgtttgct	ggaagacagc	ctcttcctct	1500
tgtaactgca	gccccagaac	ctgatctcca	catccctgcc	aggcaggtag	ctgtgtacaa	1560
gggctcatct	tcctgcccc	aacccagct	ctgatttgct	tattcagggtg	gtgtaaatac	1620
ttctaccagg	acctatttca	agccattgtg	atgtccctga	ctggggagat	gcagggcagc	1680
acaccattta	atatttccct	cacatttcca	ccccattctg	cactcttttc	tgggagttgc	1740
tgtctcagag	ggttggcgg	tctggtggct	caagaccata	agtaattatc	aaatacttag	1800
gaagcgacgg	gttttgagta	tttattacct	tttaaaaatg	tactttgtgg	ctaggcatgg	1860
tggctcacgc	ctgtagtccc	cgcaccggga	ggccgagggtg	ggtggattgc	ttgagctcag	1920
gagttcaaga	ccagcctggg	caacacggcg	aaacccagtc	tctacaaaaa	atacacacac	1980
acacacacac	acacacacac	acacacacac	acacacacac	aaattggcct	agcgtggtgt	2040
cgtgtgtctg	tggtcgcagt	tactcaggag	accaaggtag	gaggtaggaa	accaaggtag	2100
gaggatcacc	cgaggtcggt	agttcgagac	cagcctgacc	aacatggaga	aaccctgtct	2160
ttactaaaaa	tacaaaatta	gctgggcgtg	gtggtgcatg	cctgtaattc	cagctacttg	2220
ggaggctgag	acaggagaat	ggcttgaacc	cggaaggcgg	agtttgcgg	gagctgagat	2280
cgcgtcattg	cactccagcc	tgggcaacaa	gagcaaaact	ccgtctcaaa	aaaaaagaaa	2340

tatatatata	tatgtgtgtg	tgtgtgtgtg	tgtgtgtatg	tatatatata	tatgtatgtg	2400
tatatatatg	tatgtgtgtg	tgtgtgcata	tatatatata	cactttgttt	aattgtaagt	2460
gtgttttagtt	taatttttta	taatgtccgt	gattaacagc	tggctggcaa	gattcctgag	2520
aactgaagag	tttccccag	cccatccagc	acaccatggg	cccagggcag	accttggggc	2580
taggcggtct	tgggttccag	agggctccca	tgccctgtc	ctattgctct	tctggcaata	2640
ggacatttac	gcgggggggg	ggggtggttc	ttgattctgg	gtcttttagg	ggactctgtg	2700
attaagaaac	agcagggatg	ttgcaacagc	agggatgagg	tgggcctggg	gacgggtcag	2760
tgaagggtct	tcattcctag	ctgctgacct	gatctgccct	gagataaaaag	actaagaccc	2820
agagagtga	cgctgtccgc	gggggcagaa	gcgagtgagg	cgtcgggaca	gtggggcata	2880
accaagagca	aaacgcaaac	tgagacttca	gcgcgggttt	ctcgggccag	cccacgcctc	2940
ctgcctcagc	tcaatgccac	tccctccccg	ccaagtggct	ctccgctctg	gaggcgggac	3000
cgagttctcc	ggtggcccct	ggaggctccg	gcagcgagct	ctgggaggct	gggaggggag	3060
tgaggggagg	ggcgtgact	gggccgtcca	aagaggaggg	ggcctttaat	aggctcgccc	3120
agcgcctggc	ttgctgcgct	gcgagtggct	gcggttgca	gaagccgccc	ggcaccttcc	3180
gctagttctc	ggctgcaa	cttcgtcctt	gcaattgaca	gcgattgtac	ttaagctccc	3240
agggcgcgct	ttgcttgga	aggcacaggt	aggaagcgcg	ggctgccggg	tgcacgctcg	3300
ccgccctggg	aggagtctcc	ctcccttggc	tctcctttct	gggaactgcc	ggctgtcccg	3360
tagcgttggc	ggttccagag	tgcgggctgc	acggagaccg	cggcagcggc	cggagagccc	3420
ggcccagccc	cttcccacag	cgcggcgggtg	cgctgcccg	cgccatg		3467

```
<210> 26
<211> 3464
<212> DNA
<213> Homo sapiens
```

<400>	26										
ttgcacagct	aagatctggt	ggaggcatgc	acacagggcc	ctctgaccat	gggctctaaa						60
tcactgtact	atgttcctt	ccataggcct	caatcagtca	tgtaatattt	gacctggtcg						120
ttatcttagg	tattatctag	accacagatt	ttggatgcag	ttctctggct	gaagacctct						180
gagctaggat	aacccttct	cttttgacag	acgagtcaga	gaatcagatc	agtgatagaa						240

gtggagtgcc aatcctgagt atcacctcta ctcaagtgct caacatatcc ctagatcctc	300
aattccctgg caaaagtgat tggatggaac cacaggcttc caagagggga cagtcaagca	360
ttaaatacga gaatgcacat ataactcttg gtgcaatgtt tagcacatac taagcctgca	420
atacatgcta atccctttga gcaaattccac atggccagtt tctgtgctca ggggtgagaa	480
tagctgggct gtgattgggg cagggggagc actaagtggg agggacttcc tgtctcaggt	540
ccctgccatc ttgactgaca tgctgcagcc cttgccaaaa cccatgggtc agaatagaa	600
taaagtgccg ttgaaaacct tgcaatccac ctttaaaact gccgggtgta gtaaaacaat	660
tgettgcctc aaataaatga cttatcattg ctgttggttg tctgcgtttc tctttaatta	720
taggccctct ttgaacgctc aaacacacag ggcctttgta agcttgaact ccctgtctca	780
cacacagtcc tcccatacc atacactctc tttcatttgc agagtataaa caccatctc	840
tcaactcattc acataatgaa tttcagctcc ttgtgtccca atcaaggaga ggcctcactg	900
gaattatggg catctgagcc atcttcatgt tccaaggccc cagggggcgc ttccaagagt	960
ggatccttta tggggagaag ataatgggca aaaagtgtc ttcactgatg gaccagtccc	1020
agccttttct ctccctggac aatagagtcc ttccttgaa cagccacttc cctaaaaaaa	1080
attccaaaat tctcccatc catcccttt atgcttaaaa tcatcacaca ctcccttctt	1140
tgtctccccc tcttgcaaac tcaactcaga gccctttggc tccagaaaga ttttctaggt	1200
atcaggagag agtagcaaa cctccctct ctccctgcct ttctcccttg tcagagaaa	1260
aagttgattc tgcggagagg taagaaggat cttgaggtct agagcctgaa aaactccttg	1320
ggctgttctc caaactagat gggaaacataa ggtgcgattg catcttctcc agctgatact	1380
cactcggcct cctatgccag tcccagctc agggtttggc caagggtcaa atgagataat	1440
ttcatggagg aagcctggcc cgatttttct actgtttgct ggaagacagc ctcttctct	1500
tgtaactgca gccccagaac ctgatctcca catccctgcc aggcaggtag ctgtgtacaa	1560
gggctcatct tcctgcccc aacccagct ctgatttgct tattcaggtg gtgtaaatac	1620
ttctaccagg acctatttca agccattgtg atgtccctga ctggggagat gcagggcagc	1680
acaccattta atatttccct cacatttcca cccattctg cactcttttc tgggagttgc	1740
tgtctcagag ggttgccggg tctggtggct caagaccata agtaattatc aaataactag	1800
gaagcgacgg gttttgagta tttattacct tttaaaaatg tactttgtgg ctaggcattg	1860
tggctcacgc ctgtagtccc cgcaccggga ggccgaggtg ggtggattgc ttgagctcag	1920
gagttcaaga ccagcctggg caacacggcg aaaccagtc tctacaaaa atacacacac	1980
acacacacac acacacacac acacacacac acacacacaa attggcctag cgtgggtgtcg	2040

<212> DNA
<213> Homo sapiens

<220>
<221> promoter
<222> (1)..(3470)
<223>

<400> 28
ttgcacagct aagatctggt ggaggcatgc acacagggcc ctctgaccat gggctctaaa 60
tcaactgtact atgttcctt ccataggcct caatcagtca tgtaatat ttt gacctggctg 120
ttatotttagg tattatctag accacagatt ttggatgcag ttctctggct gaagacctct 180
gagctaggat accccttctc ttttgacaga cgagtcagag aatcagatca gtgatagaag 240
tggagtgcc aatcctgagta tcacctctac tcaagtgtc aacatatccc tagatcctca 300
attccctggc aaaagtgatt ggatggaacc acaggcttcc aagaggggac agtcaagcat 360
taaatacgag aatgcacata taactcttgg tgcaatgttt agcacatact aagcctgcaa 420
tacatgctaa tccctttgag caaatccaca tggccagttt ctgtgctcag gggtgagaat 480
agctgggctg tgattggggc agggggagca ctaagtggga gggacttcct gtctcaggtc 540
cctgccatct tgactgacat gctgcagccc ttgccaaaac ccatgggtca gaatgaaagt 600
aaagtgccgt tgaaaacctt gcaatccacc tttaaaactg ccgggtgtag taaaacaatt 660
gcttgcccca aataaatgac ttatcattgc tgttggttgt ctgcgtttct ctttaattat 720
aggccctctt tgaacgtca aacacacagg gcctttgtaa gcttgaactc cctgtctcac 780
acacagtcct cccataccca tacactctct ttcatttgca gagtataaac acccatctct 840
cactcattca cataatgaat ttcagctcct tgtgtcccaa tcaaggagag gcctcactgg 900
aattatgggc atctgagcca tcttcatgtt ccaaggcccc agggggcgct tccaagagtg 960
gatcctttat ggggagaaga taatgggcaa aaagtgtctt tcaactgatg accagtccca 1020
gccttttctc tccttggaca atagagttct tcccttgaac agccacttcc ctaaaaaaaaa 1080
ttccaaaatt ctccacatc atccccctta tgcttaaaat catcacacac tcccttcttt 1140
gtcctcccct cttgcaaact caactcagag ccctttggct ccagaaagat tttctaggta 1200
tcaggagaga gtagcaaagc ctccctctc tccttgctt tctcccttgt cagagaaaga 1260
agttgattct gcggagaggt aagaaggatc ttgaggtcta gagcctgaaa aactccttgg 1320
gctgttctcc aaactagatg ggaacataag gtgcgattgc atcttctcca gctgatactc 1380
actcggcctc ctatgccagt cccagtcga ggggttggtc aaggggtcaa tgagataatt 1440
tcatggagga agcctggccc gatttttcta ctgtttgctg gaagacagcc tcttcctctt 1500

tcgccgccct gggaggagtc tccctccctt ggctctcctt tctgggaact gccggctgtc 3360
 ccgtagcggtt ggcgggttcca gagtgcgggc tgcacggaga ccgcggcagc ggccggagag 3420
 cccggcccag ccccttccca cagcgcggcg gtgcgctgcc cggcgccatg 3470

<210> 29
 <211> 3467
 <212> DNA
 <213> Homo sapiens

<220>
 <221> promoter
 <222> (1)..(3467)
 <223>

<400> 29
 ttgcacagct aagatctggt ggaggcatgc acacagggcc ctctgaccat gggctctaaa 60
 tcaactgtact atgttccctt ccataggcct caatcagtca tgtaatatctt gacctggtcg 120
 ttatcttagg tattatctag accacagatt ttggatgcag ttctctggct gaagacctct 180
 gagctaggat aaccccttct cttttgacag acgagtcaga gaatcagatc agtgatagaa 240
 gtggagtgcc aatcctgagt atcacctcta ctcaagtgtc caacatatcc ctagatcctc 300
 aattccctgg caaaagtgat tggatggaac cacaggcttc caagagggga cagtcaagca 360
 ttaaatacga gaatgcacat ataactcttg gtgcaatgtt tagcacatac taagcctgca 420
 atacatgcta atccctttga gcaaattccac atggccagtt tctgtgtctca ggggtgagaa 480
 tagctgggct gtgattgggg cagggggagc actaagtggg agggacttcc tgtctcaggt 540
 ccctgccatc ttgactgaca tgctgcagcc cttgccaaaa cccatgggtc agaatgaaag 600
 taaagtgccg ttgaaaacct tgcaatccac ctttaaaact gccgggtgta gtaaaacaat 660
 tgcttgcccc aaataaatga cttatcattg ctggttggtt tctgcgtttc tctttaatta 720
 taggcctctt ttgaacgctc aaacacacag ggcctttgta agcttgaact ccctgtctca 780
 cacacagtcc tcccatatcc atacactctc tttcatttgc agagtataaa caccatctc 840
 tcaactcttc acataatgaa tttcagctcc ttgtgtccca atcaaggaga ggcctcactg 900
 gaattatggg catctgagcc atcttcatgt tccaaggccc cagggggcgc ttccaagagt 960
 ggatccttta tgggggagaag ataatgggca aaaagtgtc ttactgatg gaccagtccc 1020
 agccttttct ctctttggac aatagagtgc ttcccttgaa cagccacttc cctaaaaaaa 1080
 attccaaaat tctcccacat catccccttt atgcttaaaa tcatcacaca ctcccttctt 1140
 tgtcctcccc tcttgcaaac tcaactcaga gccctttggc tccagaaaaga ttttctaggt 1200
 atcaggagag agtagcaaag cctccctcct ctcccttgct ttctcccttg tcagagaaag 1260

tgaggggagg ggcgctgact gggccgtcca aagaggaggg ggcctttaat aggctcgccc	3120
agcgccctggc ttgctgcgct gcgagtggct gcggttgca gaagccgccc ggcaccttcc	3180
gctagttctc ggctgcaaat cttcgtcctt gcacttgaca gcgattgtac ttaagctccc	3240
agggcgcgct ttgcttggaaggcacaggt aggaagcgcg ggctgccggg tgcacgctcg	3300
ccgccctggg aggagtctcc ctcccttggc tctcctttct gggaaactgcc ggctgtcccc	3360
tagcgttggc ggttccagag tgcgggctgc acggagaccg cggcagcggc cggagagccc	3420
ggcccagccc cttcccacag cgcggcggtg cgctgcccgg cgccatg	3467

<210> 30
 <211> 3462
 <212> DNA
 <213> Homo sapiens

<220>
 <221> promoter
 <222> (1)..(3462)
 <223>

<400> 30	
ttgcacagct aagatctggt ggaggcatgc acacagggcc ctctgaccat gggctctaaa	60
tcactgtact atgttccctt ccataggcct caatcagtca tgtaatatTT gacctggctg	120
ttatcttagg tattatctag accacagatt ttggatgcag ttctctggct gaagacctct	180
gagctaggat aacccttct cttttgacag acgagtcaga gaatcagatc agtgatagaa	240
gtggagtgcc aatcctgagt atcacctcta ctcaagtgct caacatatcc ctagatcctc	300
aattccctgg caaaagtgat tggatggaac cacaggcttc caagagggga cagtcaagca	360
ttaaatacga gaatgcacat ataactcttg gtgcaatgtt tagcacatac taagcctgca	420
atacatgcta atccctttga gcaaattcac atggccagtt tctgtgctca ggggtgagaa	480
tagctgggct gtgattgggg cagggggagc actaagtggg agggacttcc tgtctcaggt	540
ccctgccatc ttgactgaca tgctgcagcc cttgccaaaa cccatgggtc agaatgaaag	600
taaagtgccg ttgaaaacct tgcaatccac ctttaaaact gccgggtgta gtaaaacaat	660
tgcttgcccc aaataaatga cttatcattg ctgttggttg tctgcgtttc tctttaatta	720
taggccctct ttgaacgctc aaacacacag ggcctttgta agcttgaact ccctgtctca	780
cacacagtcc tcccatatcc atacactctc tttcatttgc agagtataaa caccatctc	840
tcactcattc acataatgaa tttcagctcc ttgtgtccca atcaaggaga ggcctcactg	900
gaattatggg catctgagcc atcttcatgt tccaaggccc cagggggcgc ttccaagagt	960

<400> 34
agagcggccg cctgctggct cagggtag ctggcgcc

38

<210> 35
<211> 38
<212> DNA
<213> Homo sapiens

<400> 35
agagcggccg cggaaccatc caccctgtgc ttgttgag

38